<PAPER><mode2 name='PMC3506948' hasDoc='yes' version='597'></mode2><article xml:lang='en' xmlns:mml='http://www.w3.org/1998/Math/MathML' xmlns:xlink='http://www.w3.org/1999/xlink' article-type='research-article'><front><journal-meta><journal-id journal-id-type='nlm-ta'>Alzheimers Res Ther</journal-id><journal-id journal-id-type='iso-abbrev'>Alzheimers Res Ther</journal-id><journal-title-group><journal-title>Alzheimer's Research &amp; Therapy</journal-title></journal-title-group><issn pub-type='epub'>1758-9193</issn><publisher><publisher-name>BioMed Central</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type='pmcid'>3506948</article-id><article-id pub-id-type='publisher-id'>alzrt137</article-id><article-id pub-id-type='pmid'>22906081</article-id><article-id pub-id-type='doi'>10.1186/alzrt137</article-id><article-categories><subj-group subj-group-type='heading'><subject>Research</subject></subj-group></article-categories><title-group><article-title><s sid='1'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Obj1' type='Obj'></CoreSc1><CoreSc2 novelty='None' atype='GSC' advantage='None' conceptID='Con1' type='Con'></CoreSc2>Pooled-DNA sequencing identifies novel causative variants in <italic>PSEN1</italic>, <italic>GRN </italic>and <italic>MAPT </italic>in a clinical early-onset and familial Alzheimer's disease Ibero-American cohort</s></article-title></title-group><contrib-group><contrib contrib-type='author' id='A1'><name><surname>Jin</surname><given-names>Sheng Chih</given-names></name><xref rid='I1' ref-type='aff'>1</xref><email>jin810@wustl.edu</email></contrib><contrib contrib-type='author' id='A2'><name><surname>Pastor</surname><given-names>Pau</given-names></name><xref rid='I2' ref-type='aff'>2</xref><xref rid='I3' ref-type='aff'>3</xref><xref rid='I4' ref-type='aff'>4</xref><email>ppastor@unav.es</email></contrib><contrib contrib-type='author' id='A3'><name><surname>Cooper</surname><given-names>Breanna</given-names></name><xref rid='I1' ref-type='aff'>1</xref><email>cooperb@psychiatry.wustl.edu</email></contrib><contrib contrib-type='author' id='A4'><name><surname>Cervantes</surname><given-names>Sebastian</given-names></name><xref rid='I2' ref-type='aff'>2</xref><email>sebcervantes@gmail.com</email></contrib><contrib contrib-type='author' id='A5'><name><surname>Benitez</surname><given-names>Bruno A</given-names></name><xref rid='I1' ref-type='aff'>1</xref><email>benitezb@psychiatry.wustl.edu</email></contrib><contrib contrib-type='author' id='A6'><name><surname>Razquin</surname><given-names>Cristina</given-names></name><xref rid='I2' ref-type='aff'>2</xref><email>crazquin@unav.es</email></contrib><contrib contrib-type='author' id='A7'><name><surname>Goate</surname><given-names>Alison</given-names></name><xref rid='I1' ref-type='aff'>1</xref><email>goatea@psychiatry.wustl.edu</email></contrib><contrib contrib-type='author' id='A8'><collab>Ibero-American Alzheimer Disease Genetics Group Researchers</collab><email>ppastor@unav.es</email></contrib><contrib contrib-type='author' corresp='yes' id='A9'><name><surname>Cruchaga</surname><given-names>Carlos</given-names></name><xref rid='I1' ref-type='aff'>1</xref><email>cruchagc@psychiatry.wustl.edu</email></contrib></contrib-group><aff id='I1'><label>1</label>Department of Psychiatry, Washington University School of Medicine, 660 South Euclid Avenue B8134, St. Louis, MO 63110, USA</aff><aff id='I2'><label>2</label>Neurogenetics Laboratory, Division of Neurosciences, Center for Applied Medical Research, University of Navarra, Campus Universitario, 31080 Pamplona, Navarra, Spain</aff><aff id='I3'><label>3</label>Department of Neurology, Clínica Universidad de Navarra, University of Navarra School of Medicine, Campus Universitario, 31080 Pamplona, Navarra, Spain</aff><aff id='I4'><label>4</label>CIBERNED, Centro de Investigación Biomédica en Red de Enfermedades Neurodegenerativas, Instituto de Salud Carlos III, C/Sinesio Delgado, 4, 28029, Madrid, Spain</aff><pub-date pub-type='collection'><year>2012</year></pub-date><pub-date pub-type='epub'><day>20</day><month>8</month><year>2012</year></pub-date><volume>4</volume><issue>4</issue><fpage>34</fpage><lpage>34</lpage><history><date date-type='received'><day>8</day><month>6</month><year>2012</year></date><date date-type='rev-recd'><day>9</day><month>7</month><year>2012</year></date><date date-type='accepted'><day>20</day><month>8</month><year>2012</year></date></history><permissions><copyright-statement>Copyright ©2012 Jin et al.; licensee BioMed Central Ltd.</copyright-statement><copyright-year>2012</copyright-year><copyright-holder>Jin et al.; licensee BioMed Central Ltd.</copyright-holder><license license-type='open-access' xlink:href='http://creativecommons.org/licenses/by/2.0'><license-p>This is an open access article distributed under the terms of the Creative Commons Attribution License (<ext-link ext-link-type='uri' xlink:href='http://creativecommons.org/licenses/by/2.0'>http://creativecommons.org/licenses/by/2.0</ext-link>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.</license-p></license></permissions><self-uri xlink:href='http://alzres.com/content/4/4/34'></self-uri><abstract><sec><title>Introduction</title><p><s sid='2'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Bac1' type='Bac'></CoreSc1>Some familial Alzheimer's disease (AD) cases are caused by rare and highly-penetrant mutations in <italic>APP</italic>, <italic>PSEN1</italic>, and <italic>PSEN2</italic>.</s><s sid='3'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Bac1' type='Bac'></CoreSc1> Mutations in <italic>GRN </italic>and <italic>MAPT</italic>, two genes associated with frontotemporal dementia (FTD), have been found in clinically diagnosed AD cases.</s><s sid='4'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Bac1' type='Bac'></CoreSc1> Due to the dramatic developments in next-generation sequencing (NGS), high-throughput sequencing of targeted genomic regions of the human genome in many individuals in a single run is now cheap and feasible.</s><s sid='5'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Bac1' type='Bac'></CoreSc1> Recent findings favor the <italic>rare variant-common disease </italic>hypothesis by which the combination effects of rare variants could explain a large proportion of the heritability.</s><s sid='6'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Goa1' type='Goa'></CoreSc1> We utilized NGS to identify rare and pathogenic variants in <italic>APP</italic>, <italic>PSEN1</italic>, <italic>PSEN2</italic>, <italic>GRN</italic>, and <italic>MAPT </italic>in an Ibero-American cohort.</s></p></sec><sec><title>Methods</title><p><s sid='7'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Exp1' type='Exp'></CoreSc1>We performed pooled-DNA sequencing of each exon and flanking sequences in <italic>APP, PSEN1, PSEN2, MAPT </italic>and <italic>GRN </italic>in 167 clinical and 5 autopsy-confirmed AD cases (15 familial early-onset, 136 sporadic early-onset and 16 familial late-onset) from Spain and Uruguay using NGS.</s><s sid='8'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Exp1' type='Exp'></CoreSc1> Follow-up genotyping was used to validate variants.</s><s sid='9'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Exp1' type='Exp'></CoreSc1> After genotyping additional controls, we performed segregation and functional analyses to determine the pathogenicity of validated variants.</s></p></sec><sec><title>Results</title><p><s sid='10'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Obs1' type='Obs'></CoreSc1>We identified a novel G to T transition (g.38816G&gt;T) in exon 6 of <italic>PSEN1 </italic>in a sporadic early-onset AD case, resulting in a previously described pathogenic p.L173F mutation.</s><s sid='11'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Obs1' type='Obs'></CoreSc1> A pathogenic p.L392V mutation in exon 11 was found in one familial early-onset AD case.</s><s sid='12'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Res1' type='Res'></CoreSc1> We also identified a novel CC insertion (g.10974_10975insCC) in exon 8 of <italic>GRN</italic>, which introduced a premature stop codon, resulting in nonsense-mediated mRNA decay.</s><s sid='13'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Res1' type='Res'></CoreSc1> This <italic>GRN </italic>mutation was associated with lower GRN plasma levels, as previously reported for other <italic>GRN </italic>pathogenic mutations.</s><s sid='14'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Res1' type='Res'></CoreSc1> We found two variants in <italic>MAPT </italic>(p.A152T, p.S318L) present only in three AD cases but not controls, suggesting that these variants could be risk factors for the disease.</s></p></sec><sec><title>Conclusions</title><p><s sid='15'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Con1' type='Con'></CoreSc1>We found pathogenic mutations in <italic>PSEN1</italic>, <italic>GRN </italic>and <italic>MAPT </italic>in 2.33% of the screened cases.</s><s sid='16'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Con1' type='Con'></CoreSc1> This study suggests that pathogenic mutations or risk variants in <italic>MAPT </italic>and in <italic>GRN </italic>are as frequent in clinical AD cases as mutations in <italic>APP</italic>, <italic>PSEN1 </italic>and <italic>PSEN2</italic>, highlighting that pleiotropy of <italic>MAPT </italic>or <italic>GRN </italic>mutations can influence both FTD and AD phenotypic traits.</s></p></sec></abstract></article-meta></front><body><sec><title>Introduction</title><p><s sid='17'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Bac1' type='Bac'></CoreSc1>Alzheimer's disease (AD) is the most common form of dementia, affecting more than 13% of individuals age 65 years or older and 30% to 50% of individuals age 80 or older [<xref rid='B1' ref-type='bibr'>1</xref>,<xref rid='B2' ref-type='bibr'>2</xref>].</s><s sid='18'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Bac1' type='Bac'></CoreSc1> The number of affected individuals is estimated to double by 2025; thus, AD is rapidly becoming a serious threat to health care in developed countries [<xref rid='B2' ref-type='bibr'>2</xref>].</s><s sid='19'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Bac1' type='Bac'></CoreSc1> Since the number of patients and health-care costs are projected to increase significantly, effective therapies are urgently needed.</s><s sid='20'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Mot1' type='Mot'></CoreSc1> Understanding how genetic risk factors affect the disease process will help to identify novel targets for therapies, to elucidate the nature of aging, and to extend the healthy active life span.</s></p><p><s sid='21'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Bac1' type='Bac'></CoreSc1>AD is often classified on the basis of the age at onset (AAO); early-onset AD (EOAD) is defined as AAO of not more than 65 years, and late-onset AD (LOAD) is defined as AAO of more than 65 years.</s><s sid='22'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Bac1' type='Bac'></CoreSc1> Even though 99% of AD cases are late-onset, studies of rare autosomal dominant familial EOAD have provided valuable insights into the pathogenesis of AD.</s><s sid='23'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Bac1' type='Bac'></CoreSc1> Mutations in amyloid-β precursor protein (<italic>APP</italic>), presenilin 1 (<italic>PSEN1</italic>), and presenilin 2 <italic>(PSEN2</italic>) were initially discovered in familial EOAD, although additional studies have also identified pathogenic mutations in these genes in late-onset families in addition to the APOE4 allele [<xref rid='B3' ref-type='bibr'>3</xref>-<xref rid='B9' ref-type='bibr'>9</xref>].</s><s sid='24'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Bac1' type='Bac'></CoreSc1> Progranulin (<italic>GRN</italic>) and microtubule-associated protein tau (<italic>MAPT</italic>) mutations are associated with familial frontotemporal dementia, but recently some have also been found in clinically diagnosed AD cases [<xref rid='B10' ref-type='bibr'>10</xref>,<xref rid='B11' ref-type='bibr'>11</xref>], and a recent study suggested that mutations in <italic>MAPT </italic>and <italic>GRN </italic>can be found in clinical AD with a frequency comparable to that of mutations in <italic>APP</italic>, <italic>PSEN1</italic>, and <italic>PSEN2 </italic>[<xref rid='B7' ref-type='bibr'>7</xref>].</s></p><p><s sid='25'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Goa1' type='Goa'></CoreSc1>In this study, we aimed to examine the frequency of causative mutations in autosomal dominant dementia genes in independent clinical series from Spain and Uruguay.</s><s sid='26'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Exp1' type='Exp'></CoreSc1> We performed pooled-DNA sequencing in 172 AD cases in <italic>APP</italic>, <italic>PSEN1</italic>, <italic>PSEN2</italic>, <italic>GRN</italic>, and <italic>MAPT </italic>in order to identify known pathogenic mutations and potentially functional novel variants associated with disease risk.</s><s sid='27'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Met1' type='Met'></CoreSc1> For those validated variants, follow-up genotyping was conducted in additional AD cases and non-demented older controls with Spanish ancestry to infer and compare mutation frequencies.</s><s sid='28'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Exp1' type='Exp'></CoreSc1> We also genotyped available relatives of the mutation carriers to determine whether these mutations segregate with the diagnosis of AD (Figure <xref rid='F1' ref-type='fig'>1</xref>).</s><s sid='29'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Exp1' type='Exp'></CoreSc1> Finally, enzyme-linked immunosorbent assay (ELISA) was performed to test the association between the status of the novel <italic>GRN </italic>mutation and <italic>GRN </italic>plasma levels.</s></p><fig id='F1' position='float'><label>Figure 1</label><caption><p><bold>Schematic of the study design</bold>. Pooled-DNA sequencing was performed in a single DNA pool of 172 individuals to identify known pathogenic or novel functional variants by using Illumina HiSeq 2000. The SPLINTER software was used to call the variants. High-confident variants were selected for Sequenom genotyping. For those validated functional variants, follow-up genotyping was performed in large case-control series to infer and compare the frequencies. Segregation analysis was then performed to determine whether disease status segregates with risk alleles. Enzyme-linked immunosorbent assays (ELISAs) were used to evaluate the impact of novel <italic>GRN </italic>splice-site mutation on the changes of <italic>GRN </italic>plasma levels. <italic>GRN</italic>, progranulin; SPLINTER, short indel prediction by large deviation inference and nonlinear true frequency estimation by recursion.</p></caption><graphic xlink:href='alzrt137-1'></graphic></fig></sec><sec sec-type='materials|methods'><title>Materials and methods</title><sec><title>Sample selection</title><p><s sid='30'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Exp1' type='Exp'></CoreSc1>DNA was collected from subjects of Spanish descent who were recruited between 2000 and 2010 from the departments of neurology of the collaborating centers from Spain (n = 161) and Uruguay (n = 11).</s><s sid='31'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Met1' type='Met'></CoreSc1> Samples were selected from individuals with neuropathologically confirmed AD or from individuals with the earliest AAO along with a diagnosis of probable AD within a family.</s><s sid='32'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Obj1' type='Obj'></CoreSc1> The cohort included 15 (8.98%) familial EOAD, 136 (81.44%) sporadic EOAD, and 16 (9.58%) familial LOAD cases and five others who were autopsy-confirmed AD cases (Table <xref rid='T1' ref-type='table'>1</xref>).</s><s sid='33'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Met1' type='Met'></CoreSc1> Diagnosis of probable AD was made in accordance with standard clinical research criteria [<xref rid='B12' ref-type='bibr'>12</xref>].</s><s sid='34'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Bac1' type='Bac'></CoreSc1> All individuals gave their written informed consent for participating in the study, which was approved by the institutional review board of Washington University in St. Louis.</s></p><table-wrap id='T1' position='float'><label>Table 1</label><caption><p>Demographic characteristics of the cohort of 172 sequenced samples</p></caption><table rules='groups' frame='hsides'><tbody><tr><td align='left'><bold>Demographic characteristics</bold></td><td></td><td></td></tr><tr><td align='left'>Age at onset of AD</td><td align='center'>Years</td><td></td></tr><tr><td align='left'> Mean</td><td align='center'>59.56</td><td></td></tr><tr><td align='left'> Standard deviation</td><td align='center'>8.19</td><td></td></tr><tr><td align='left'> Range</td><td align='center'>29.5-87.5</td><td></td></tr><tr><td></td><td></td><td></td></tr><tr><td></td><td align='center'>Number</td><td align='center'>Percentage</td></tr><tr><td align='left'>Diagnosis</td><td></td><td></td></tr><tr><td align='left'> Familial early-onset AD (onset ≤65 years)</td><td align='center'>15</td><td align='center'>8.98%</td></tr><tr><td align='left'> Sporadic early-onset AD (onset ≤65 years)</td><td align='center'>136</td><td align='center'>81.44%</td></tr><tr><td align='left'> Familial late-onset AD (onset &gt;65 years)</td><td align='center'>16</td><td align='center'>9.58%</td></tr><tr><td></td><td></td><td></td></tr><tr><td align='left'> Clinical AD</td><td align='center'>167</td><td align='center'>97.09%</td></tr><tr><td align='left'> Autopsy-confirmed</td><td align='center'>5</td><td align='center'>2.91%</td></tr><tr><td align='left'>APOE</td><td></td><td></td></tr><tr><td align='left'> ε2ε2+ε2ε3</td><td align='center'>3</td><td align='center'>1.75%</td></tr><tr><td align='left'> ε3ε3</td><td align='center'>79</td><td align='center'>45.93%</td></tr><tr><td align='left'> ε3ε4</td><td align='center'>66</td><td align='center'>38.37%</td></tr><tr><td align='left'> ε4ε4</td><td align='center'>24</td><td align='center'>13.95%</td></tr><tr><td align='left'>Birth country</td><td></td><td></td></tr><tr><td align='left'> Spain</td><td align='center'>161</td><td align='center'>93.60%</td></tr><tr><td align='left'> Uruguay</td><td align='center'>11</td><td align='center'>6.40%</td></tr><tr><td align='left'>Gender</td><td></td><td></td></tr><tr><td align='left'> Male</td><td align='center'>62</td><td align='center'>36.05%</td></tr><tr><td align='left'> Female</td><td align='center'>105</td><td align='center'>61.05%</td></tr><tr><td align='left'> Unknown</td><td align='center'>5</td><td align='center'>2.91%</td></tr></tbody></table><table-wrap-foot><p>AD, Alzheimer's disease; APOE, apolipoprotein E.</p></table-wrap-foot></table-wrap></sec><sec><title>Pooled sequencing</title><p><s sid='35'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Exp1' type='Exp'></CoreSc1>Pooled-DNA sequencing was performed as previously described [<xref rid='B7' ref-type='bibr'>7</xref>,<xref rid='B13' ref-type='bibr'>13</xref>].</s><s sid='36'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Exp1' type='Exp'></CoreSc1> The concentration of genomic DNA was quantified by Quant-iT™ PicoGreen (Invitrogen Corporation, Carlsbad, CA, USA) reagent, and normalized amounts of individual DNA samples were pooled.</s><s sid='37'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Exp1' type='Exp'></CoreSc1> A single DNA pool with 172 individuals was used as a template for polymerase chain reaction (PCR) amplification of coding regions of genes <italic>APP</italic>, <italic>PSEN1</italic>, <italic>PSEN2</italic>, <italic>MAPT</italic>, and <italic>GRN</italic>.</s><s sid='38'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Exp1' type='Exp'></CoreSc1> PRIMER3 software was used to design the primers for amplification of each exon.</s><s sid='39'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Exp1' type='Exp'></CoreSc1> To ensure complete coverage of each exon, primers were at least 50 base pairs (bp) from the intron-exon boundary.</s><s sid='40'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Exp1' type='Exp'></CoreSc1> Pfu (Agilent Technologies, Santa Clara, CA, USA) enzyme was used for all PCRs to reduce the likelihood of PCR-induced sequence variants.</s><s sid='41'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Exp1' type='Exp'></CoreSc1> After PCR amplification of selected genomic regions, each PCR product was purified by using QIAquick PCR (Qiagen Inc., Valencia, CA, USA) purification kits and quantified by using Quant-iT™ PicoGreen reagent.</s><s sid='42'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Exp1' type='Exp'></CoreSc1> The PCR products were combined into one pool in equimolar amounts and ligated by using T4 ligase and T4 Polynucleotide Kinase [<xref rid='B14' ref-type='bibr'>14</xref>].</s><s sid='43'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Exp1' type='Exp'></CoreSc1> At this stage, negative control and positive control amplicons were also added to the pool to generate the error model and to construct the optimal significant cutoff, respectively.</s><s sid='44'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Exp1' type='Exp'></CoreSc1> Ligated concatemers were randomly fragmented by sonication and prepared for Illumina sequencing on an Illumina HiSeq2000 (Illumina, Inc., San Diego, CA, USA) in accordance with the protocol of the manufacturer.</s><s sid='45'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Met1' type='Met'></CoreSc1> The fold coverage necessary to achieve the optimal positive predictive value for the SNP-calling algorithm was calculated, and a sequencing coverage of 30X per haploid genome was targeted in this study, consistent with the previous finding [<xref rid='B14' ref-type='bibr'>14</xref>].</s><s sid='46'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Exp1' type='Exp'></CoreSc1> Two lanes of Illumina HiSeq2000 sequencing were run to obtain a minimum of 30-fold coverage per allele.</s></p></sec><sec><title>Sequencing analysis</title><p><s sid='47'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Met1' type='Met'></CoreSc1>Sequencing reads (42-bp reads) were mapped back to the reference sequence (GRCh37/hg19) allowing up to three mismatches by using an alignment algorithm developed by Vallania and colleagues [<xref rid='B14' ref-type='bibr'>14</xref>].</s><s sid='48'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Met1' type='Met'></CoreSc1> To determine the sensitivity and specificity of this method, positive and negative control vectors were included as PCR products in the pooled-DNA sequencing protocol described above.</s><s sid='49'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Met1' type='Met'></CoreSc1> The negative control reads were used to build up the error model used in the variant calling step, whereas the positive control reads were used to calculate the significant cutoff for optimizing specificity and sensitivity of the analysis.</s><s sid='50'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Met1' type='Met'></CoreSc1> The SPLINTER (short indel prediction by large deviation inference and nonlinear true frequency estimation by recursion) program was used to predict and quantify short insertions, deletions, and substitutions present in the pool.</s><s sid='51'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Met1' type='Met'></CoreSc1> The segregated variants were called by comparing the observed frequency vector to the expected frequency vector calculated by the error model.</s><s sid='52'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Met1' type='Met'></CoreSc1> The maximum likelihood method was used to estimate variant frequencies in the pool samples.</s><s sid='53'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Met1' type='Met'></CoreSc1> SIFT2 was used to predict the effect of variants on protein structure and function, and the Alzheimer Disease &amp; Frontotemporal Dementia (AD&amp;FTD) mutation database [<xref rid='B15' ref-type='bibr'>15</xref>] was used to annotate the known pathogenic variants.</s><s sid='54'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Met1' type='Met'></CoreSc1> The Exome Variant Server (EVS) [<xref rid='B16' ref-type='bibr'>16</xref>], SeattleSeq Annotation [<xref rid='B17' ref-type='bibr'>17</xref>], and 1000 Genomes Project were finally used to exclude known variants.</s><s sid='55'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Exp1' type='Exp'></CoreSc1> Novel and potentially functional variants were selected for direct genotyping by using Sequenom iPLEX (Sequenom, San Diego, CA, USA).</s></p></sec><sec><title>Genotyping and segregation analysis</title><p><s sid='56'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Exp1' type='Exp'></CoreSc1>All rare (minor allele frequency of less than 5%) missense, splice-site, and previously identified pathogenic variants called in the pooled-DNA sequencing were genotyped by using Sequenom iPLEX in accordance with standard protocols.</s><s sid='57'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Met1' type='Met'></CoreSc1> We genotyped validated variants in all available family members to determine whether these variants segregate with disease status.</s><s sid='58'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Met1' type='Met'></CoreSc1> Common and synonymous variants were not followed up.</s></p></sec><sec><title>GRN plasma level measurement</title><p><s sid='59'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Exp1' type='Exp'></CoreSc1><italic>GRN </italic>plasma levels were measured in duplicate by using an ELISA kit (Human Progranulin ELISA Kit; AdipoGen Inc., Seoul, Korea).</s></p></sec></sec><sec sec-type='results'><title>Results</title><p><s sid='60'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Exp1' type='Exp'></CoreSc1>To identify known pathogenic mutations and novel rare variants, pooled-DNA sequencing was performed for the coding exons and their corresponding flanking regions for <italic>APP</italic>, <italic>PSEN1</italic>, <italic>PSEN2</italic>, <italic>MAPT</italic>, and <italic>GRN </italic>in a total of 15 (8.98%) familial EOAD, 136 (81.44%) sporadic EOAD, 16 (9.58%) familial LOAD, and five autopsy-confirmed AD cases (Table <xref rid='T1' ref-type='table'>1</xref>).</s><s sid='61'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Exp1' type='Exp'></CoreSc1> For familial cases, a single index case per family was sequenced.</s><s sid='62'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Exp1' type='Exp'></CoreSc1> Seventy exons covering 45.3 kb of the target region of <italic>APP</italic>, <italic>PSEN1</italic>, <italic>PSEN2</italic>, <italic>GRN</italic>, and <italic>MAPT </italic>were PCR-amplified by using specific primers and then pooled in equimolar amounts.</s><s sid='63'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Exp1' type='Exp'></CoreSc1> The pooled amplicons were concatenated and sheared to construct libraries and then sequenced on Illumina HiSeq2000 by using two lanes.</s></p><p><s sid='64'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Met1' type='Met'></CoreSc1>We used the SPLINTER software to perform alignment and call rare variants in the pooled samples [<xref rid='B14' ref-type='bibr'>14</xref>].</s><s sid='65'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Exp1' type='Exp'></CoreSc1> Sequencing reads were mapped back to the reference genome (GRCh37/hg19) by gapped alignments allowing up to 3-bp mismatches by using the SPLINTER aligner.</s><s sid='66'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Exp1' type='Exp'></CoreSc1> The Illumina sequencing produced 181,854,451 reads in two lanes, and the aligner was able to map 155,431,194 reads (85.5%) back to the reference, resulting in an average 149.8-fold coverage per amplicon (corresponding to 143.5-fold coverage per allele).</s></p><p><s sid='67'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Goa1' type='Goa'></CoreSc1>Since our goal was to identify novel or functional rare variants, 12 missense, splice-site, or previously confirmed pathogenic variants were selected for direct genotyping by using Sequenom iPLEX (Table <xref rid='T2' ref-type='table'>2</xref>).</s><s sid='68'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Obs1' type='Obs'></CoreSc1> These 12 variants were found in 34 out of 172 (19.77%) AD cases and 12 out of 139 (8.63%) non-demented older controls of Spanish descent (Table <xref rid='T2' ref-type='table'>2</xref>).</s></p><table-wrap id='T2' position='float'><label>Table 2</label><caption><p>Frequencies of validated variants in the pooled sequencing and follow-up case control series of Spanish descent</p></caption><table rules='groups' frame='hsides'><thead><tr><th align='center'>Gene-Exon</th><th align='center'>AA change</th><th align='center'>rs ID</th><th align='center'>Codonchange</th><th align='center'>AD&amp;FTD<sup>a</sup></th><th colspan='3' align='center'>Alzheimer's disease cases</th><th align='center'>Controls</th></tr><tr><th></th><th></th><th></th><th></th><th></th><th colspan='4'><hr></hr></th></tr><tr><th></th><th></th><th></th><th></th><th></th><th align='center'>Count (%)</th><th align='center'>AAO range, years</th><th align='center'>Diagnoses<sup>b</sup></th><th align='center'>Count (%)</th></tr></thead><tbody><tr><td align='center'><italic>GRN</italic>-8</td><td align='center'>Ile256IlefsX27</td><td align='center'>-</td><td align='center'>[-/CC]</td><td align='center'>-</td><td align='center'>1/176 (0.57)</td><td align='center'>60.5</td><td align='center'>1 FL</td><td align='center'>0/459 (0)</td></tr><tr><td align='center'><italic>MAPT</italic>-10</td><td align='center'>GTC-aTC</td><td align='center'>149280278</td><td align='center'>V287I</td><td align='center'>-</td><td align='center'>2/176 (1.14)</td><td align='center'>64.5-70.5</td><td align='center'>1 SE and 1 FL</td><td align='center'>0/534 (0)</td></tr><tr><td align='center'><italic>MAPT</italic>-4A</td><td align='center'>TCG-TtG</td><td align='center'>73314997</td><td align='center'>S318L</td><td align='center'>-</td><td align='center'>1/176 (0.57)</td><td align='center'>64.5</td><td align='center'>1 SE</td><td align='center'>0/139 (0)</td></tr><tr><td align='center'><italic>MAPT</italic>-4A</td><td align='center'>GGG-aGG</td><td align='center'>76375268</td><td align='center'>G213R</td><td align='center'>-</td><td align='center'>1/176 (0.57)</td><td align='center'>64.5</td><td align='center'>1 SE</td><td align='center'>0/139 (0)</td></tr><tr><td align='center'><italic>MAPT</italic>-4A</td><td align='center'>GTC-GgC</td><td align='center'>141120474</td><td align='center'>V224G</td><td align='center'>-</td><td align='center'>3/176 (1.7)</td><td align='center'>58.5-72.5</td><td align='center'>1 FE and 2 FL</td><td align='center'>1/139 (0.72)</td></tr><tr><td align='center'><italic>MAPT</italic>-4A</td><td align='center'>CAA-CgA</td><td align='center'>63750072</td><td align='center'>Q230R</td><td align='center'>-</td><td align='center'>18/176 (10.23)</td><td align='center'>50.5-83.5</td><td align='center'>1 AC, 2 FE, 2 FL, and 13 SE</td><td align='center'>8/139 (5.8)</td></tr><tr><td align='center'><italic>MAPT</italic>-4A</td><td align='center'>GCC-GtC</td><td align='center'>-</td><td align='center'>A297V</td><td align='center'>-</td><td align='center'>1/176 (0.57)</td><td align='center'>59.5</td><td align='center'>1 FE</td><td align='center'>0/139 (0)</td></tr><tr><td align='center'><italic>MAPT</italic>-7</td><td align='center'>GCC-aCC</td><td align='center'>143624519</td><td align='center'>A152T</td><td align='center'>-</td><td align='center'>2/176 (1.14)</td><td align='center'>57.5</td><td align='center'>1 AC and 1 SE</td><td align='center'>0/139 (0)</td></tr><tr><td align='center'><italic>PSEN1</italic>-5</td><td align='center'>ATG-AcG</td><td align='center'>63751106</td><td align='center'>M139T</td><td align='center'>Pathogenic</td><td align='center'>1/176 (0.57)</td><td align='center'>47.5</td><td align='center'>1 SE</td><td align='center'>0/459 (0)</td></tr><tr><td align='center'><italic>PSEN1</italic>-6</td><td align='center'>TTG-TTt</td><td align='center'>-</td><td align='center'>L173F</td><td align='center'>Pathogenic</td><td align='center'>1/176 (0.57)</td><td align='center'>50.5</td><td align='center'>1 SE</td><td align='center'>0/459 (0)</td></tr><tr><td align='center'><italic>PSEN1</italic>-9</td><td align='center'>GAA-GgA</td><td align='center'>17125721</td><td align='center'>E318G</td><td align='center'>Not pathogenic</td><td align='center'>2/176 (1.14)</td><td align='center'>56.5-65.5</td><td align='center'>2 SE</td><td align='center'>3/139 (2.2)</td></tr><tr><td align='center'><italic>PSEN1</italic>-11</td><td align='center'>CTG-gTG</td><td align='center'>63751416</td><td align='center'>L392V</td><td align='center'>Pathogenic</td><td align='center'>1/176 (0.57)</td><td align='center'>42.5</td><td align='center'>1 FE</td><td align='center'>Not available</td></tr></tbody></table><table-wrap-foot><p><sup>a</sup>Alzheimer Disease &amp; Frontotemporal Dementia mutation database [<xref rid='B15' ref-type='bibr'>15</xref>]. <sup>b</sup>This column summarizes the status of carriers in Alzheimer's disease cases. AAO, age at onset; AC, autopsy-confirmed Alzheimer's disease; FE, familial early-onset Alzheimer's disease; FL, familial late-onset Alzheimer's disease; <italic>GRN</italic>, progranulin; <italic>MAPT</italic>, microtubule-associated protein tau; <italic>PSEN1</italic>, presenilin 1; SE, sporadic early-onset Alzheimer's disease; SL, sporadic late-onset Alzheimer's disease.</p></table-wrap-foot></table-wrap><p><s sid='69'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Obs1' type='Obs'></CoreSc1>Four missense mutations (p.M139T, p.L173F, p.E318G, and p.L392V) in <italic>PSEN1 </italic>were validated (Table <xref rid='T2' ref-type='table'>2</xref>).</s><s sid='70'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Bac1' type='Bac'></CoreSc1> The p.M139T mutation located in exon 5 of <italic>PSEN1 </italic>and the p.L392V mutation in exon 11 have been shown to be pathogenic in previous studies [<xref rid='B5' ref-type='bibr'>5</xref>,<xref rid='B18' ref-type='bibr'>18</xref>-<xref rid='B24' ref-type='bibr'>24</xref>].</s><s sid='71'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Obs1' type='Obs'></CoreSc1> The p.M139T carrier, who had a ε3/ε3 genotype, was a sporadic EOAD case with an AAO of 47.5 years, which is close to the mean AAO of disease in three previously reported families (one French family and two independent Spanish families).</s><s sid='72'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Obs1' type='Obs'></CoreSc1> The p.L392V mutation, which has been identified in five families (one Italian family, one French, one Japanese, and two unknown), was confirmed in a familial EOAD case with the <italic>APOE </italic>ε3/ε4 genotype and AAO of 42.5, which is similar to the mean AAO in these five families [<xref rid='B5' ref-type='bibr'>5</xref>,<xref rid='B18' ref-type='bibr'>18</xref>,<xref rid='B19' ref-type='bibr'>19</xref>,<xref rid='B22' ref-type='bibr'>22</xref>-<xref rid='B24' ref-type='bibr'>24</xref>].</s><s sid='73'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Obs1' type='Obs'></CoreSc1> We also found a novel G-to-T transition (g.38816G&gt;T) in exon 6 of <italic>PSEN1</italic>, resulting in a previously described pathogenic p.L173F missense mutation [<xref rid='B25' ref-type='bibr'>25</xref>].</s><s sid='74'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Obs1' type='Obs'></CoreSc1> The carrier of the p.L173F mutation in our study, who was an <italic>APOE </italic>ε3/ε3 carrier, had an AAO of 50.5 years, which is close to the mean AAO in the family reported by Kasuga and colleagues [<xref rid='B25' ref-type='bibr'>25</xref>].</s><s sid='75'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Bac1' type='Bac'></CoreSc1> The p.L173F mutation was shown to be associated with presenile dementia and parkinsonism [<xref rid='B25' ref-type='bibr'>25</xref>].</s><s sid='76'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Obs1' type='Obs'></CoreSc1> The p.M139T and p.L173F mutations in <italic>PSEN1 </italic>were not found in any additional cases or the 459 Spanish controls.</s><s sid='77'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Bac1' type='Bac'></CoreSc1> The p.E318G mutation was a low-frequency polymorphism observed at equal frequencies in patients and unaffected controls in several previous studies [<xref rid='B26' ref-type='bibr'>26</xref>-<xref rid='B28' ref-type='bibr'>28</xref>].</s><s sid='78'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Obs1' type='Obs'></CoreSc1> The p.E318G frequency in our study was higher in controls (2.16%, 3 out of 139) than in AD cases (1.14%, 2 out of 176), suggesting that p.E318G might not be a risk factor for clinical AD.</s></p><p><s sid='79'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Obs1' type='Obs'></CoreSc1>We also found a novel <italic>GRN </italic>CC insertion, g.10974_10975insCC (Ile256IlefsX27), which was not present in the AD&amp;FTD database, 1000 Genomes Project, SeattleSeq, or EVS (Figure <xref rid='F2' ref-type='fig'>2</xref>).</s><s sid='80'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Obs1' type='Obs'></CoreSc1> The CC insertion is a frameshift mutation located in exon 8 of <italic>GRN</italic>, introducing a premature stop codon 27 amino acids after the insertion site (Ile256IlefsX27).</s><s sid='81'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Hyp1' type='Hyp'></CoreSc1> Considering other frameshift mutations in <italic>GRN </italic>[<xref rid='B29' ref-type='bibr'>29</xref>-<xref rid='B33' ref-type='bibr'>33</xref>], we predicted that the mutant allele will be degraded by nonsense-mediated decay, resulting in a loss of one functional allele.</s><s sid='82'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Goa1' type='Goa'></CoreSc1> To confirm that the novel <italic>GRN </italic>frameshift mutation (Ile256IlefsX27) was related to the diagnosis of AD, we performed segregation analysis, genotyping of additional Spanish controls, and functional analysis.</s><s sid='83'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Obs1' type='Obs'></CoreSc1> The proband, the carrier of the <italic>GRN </italic>mutation with the <italic>APOE </italic>ε3/ε3 genotype, had an AAO of 60.5 years and was diagnosed with probable AD on the basis of international criteria [<xref rid='B12' ref-type='bibr'>12</xref>].</s><s sid='84'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Obs1' type='Obs'></CoreSc1> One of the proband's siblings, who had a diagnosis of probable AD, is also a carrier of the mutation.</s><s sid='85'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Obs1' type='Obs'></CoreSc1> Two other non-demented siblings of the proband did not carry the variant.</s><s sid='86'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Obs1' type='Obs'></CoreSc1> The <italic>GRN </italic>frameshift mutation was absent in 449 older healthy Spanish controls.</s></p><fig id='F2' position='float'><label>Figure 2</label><caption><p><bold>The transcript of the novel <italic>GRN </italic>mutation</bold>. A splice-site mutation with a CC-insertion (g.10974_10975insCC) in <italic>GRN </italic>exon 8 results in a premature stop codon and nonsense-mediated decay of the resultant mRNA. <italic>GRN</italic>, progranulin.</p></caption><graphic xlink:href='alzrt137-2'></graphic></fig><p><s sid='87'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Bac1' type='Bac'></CoreSc1>Previous studies have shown that individuals with pathogenic <italic>GRN </italic>mutations have lower <italic>GRN </italic>plasma levels [<xref rid='B30' ref-type='bibr'>30</xref>,<xref rid='B31' ref-type='bibr'>31</xref>,<xref rid='B34' ref-type='bibr'>34</xref>-<xref rid='B38' ref-type='bibr'>38</xref>].</s><s sid='88'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Goa1' type='Goa'></CoreSc1> Therefore, we tested whether the <italic>GRN </italic>g.10974_10975insCC mutation was associated with low <italic>GRN </italic>plasma levels.</s><s sid='89'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Met1' type='Met'></CoreSc1> The <italic>GRN </italic>plasma levels were measured in 18 individuals, including two non-demented siblings of the proband who did not carry the mutation, 11 carriers of a previously identified <italic>GRN </italic>mutation (as positive controls), and five family members who were non-carriers for <italic>GRN </italic>mutations [<xref rid='B35' ref-type='bibr'>35</xref>,<xref rid='B39' ref-type='bibr'>39</xref>,<xref rid='B40' ref-type='bibr'>40</xref>].</s><s sid='90'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Obs1' type='Obs'></CoreSc1> The <italic>GRN </italic>g.10974_10975insCC mutation carrier had an average <italic>GRN </italic>plasma level of 0.125 ng/μL, which is very close to 0.116 ng/μL, the average <italic>GRN </italic>plasma level of a known <italic>GRN </italic>mutation carrier (Figure <xref rid='F3' ref-type='fig'>3</xref>).</s><s sid='91'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Obs1' type='Obs'></CoreSc1> The two siblings of the carrier of the <italic>GRN </italic>g.10974_10975insCC mutation had an average <italic>GRN </italic>plasma level of 0.463 ng/μL, which is close to the mean <italic>GRN </italic>plasma level for the five family members who were non-carriers of the <italic>GRN </italic>mutation (0.504 ng/μL).</s><s sid='92'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Res1' type='Res'></CoreSc1> Together, these results confirm that the <italic>GRN </italic>g.10974_10975insCC mutation is pathogenic.</s></p><fig id='F3' position='float'><label>Figure 3</label><caption><p><bold>Enzyme-linked immunosorbent assays comparing <italic>GRN </italic>plasma levels between <italic>GRN </italic>mutation carriers and controls</bold>. Measurement of <italic>GRN </italic>plasma levels for a known <italic>GRN </italic>mutation (left) and the novel <italic>GRN </italic>mutation (right), Ile256IlefsX27, observed in our study compared with Alzheimer's disease cases and non-demented older controls. <italic>GRN</italic>, progranulin; mut, mutant; wt, wild-type.</p></caption><graphic xlink:href='alzrt137-3'></graphic></fig><p><s sid='93'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Met1' type='Met'></CoreSc1>Seven missense variants in <italic>MAPT </italic>were further validated in our study: five in exon 4A (p.S318L, p.G213R, p.V224G, p.Q230R, and p.A297V), one in exon 7 (p.A152T), and one in exon 10 (p.V287I).</s><s sid='94'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Obs1' type='Obs'></CoreSc1> The frequency of each variant in cases and controls is listed in Table <xref rid='T2' ref-type='table'>2</xref>. p.</s><s sid='95'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Res1' type='Res'></CoreSc1>G213R, p.V224G, p.Q230R, and p.S318L reside in exon 4A of <italic>MAPT </italic>and are present in SeattleSeq, EVS, or 1000 Genomes Project, suggesting that they do not affect risk for AD.</s><s sid='96'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Res1' type='Res'></CoreSc1> The p.A297V mutation also located in exon 4A was not found in any annotation tool, and thus the functional role of p.A297V remains unclear.</s><s sid='97'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Bac1' type='Bac'></CoreSc1> The p.A152T variant located in exon 7 was suggested in a recent study to be a risk factor for FTD-spectrum and AD in a total of 15,369 subjects [<xref rid='B41' ref-type='bibr'>41</xref>].</s><s sid='98'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Bac1' type='Bac'></CoreSc1> Another recent study shows that the p.A152T mutation increases risk for developing neurodegenerative diseases by influencing tau accumulation [<xref rid='B42' ref-type='bibr'>42</xref>].</s><s sid='99'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Obs1' type='Obs'></CoreSc1> We found two p.A152T carriers among the cases (one with ε3/ε3 and one with ε4/ε4 genotype) and none in the controls.</s><s sid='100'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Obs1' type='Obs'></CoreSc1> Segregation analysis showed that the healthy 69-year-old sibling of the AD proband did not carry the p.A152T mutation.</s><s sid='101'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Bac1' type='Bac'></CoreSc1> No family history for the other MAPT p.A152T carrier was reported, but autopsy was available for this individual.</s><s sid='102'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Obs1' type='Obs'></CoreSc1> Fresh brain weight was 924 g.</s><s sid='103'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Obs1' type='Obs'></CoreSc1> A macroscopic examination revealed moderate global cortical atrophy, and serial coronal sections of the left hemisphere showed moderate ventricular dilatation and atrophy of the medial temporal lobe, particularly in its anterior segment.</s><s sid='104'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Obs1' type='Obs'></CoreSc1> A histological examination based on immunohistochemistry for tau and beta-amyloid revealed a high density of neuritic plaques in associative isocortical areas, a dense distribution of neurofibrillary tangles consistent with Braak stage VI, and moderate amyloid angiopathy.</s><s sid='105'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Obs1' type='Obs'></CoreSc1> Additionally, immunostaining for alpha-synuclein displayed abundant Lewy bodies and neurites at the amygdaloid complex and enthorrinal cortex and a moderate density of inclusions in the parahippocampal and cyngular cortices and in brainstem nuclei.</s><s sid='106'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Bac1' type='Bac'></CoreSc1> These findings are consistent with a neuropathological diagnosis of Alzheimer's type changes with a high probability of disease, combined with Lewy type pathology of the limbic predominant subtype [<xref rid='B43' ref-type='bibr'>43</xref>].</s></p><p><s sid='107'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Res1' type='Res'></CoreSc1>These results suggest that p.A152T contributes to an increased risk associated with clinical AD.</s><s sid='108'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Hyp1' type='Hyp'></CoreSc1> The p.S318L variant, located in exon 10 of <italic>MAPT</italic>, was found in two cases (one with ε3/ε3 and one with ε3/ε4 genotype) and none of 534 ethnicity-matched controls, suggesting that p.S318L might increase the risk for clinical AD.</s><s sid='109'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Mot1' type='Mot'></CoreSc1> However, studies with a larger sample size are needed to confirm its role in AD risk.</s></p></sec><sec sec-type='discussion'><title>Discussion</title><p><s sid='110'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Res1' type='Res'></CoreSc1>Our study has shown that pooled-DNA sequencing can effectively identify known and novel pathogenic variants.</s><s sid='111'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Bac1' type='Bac'></CoreSc1> So far, around 344 different mutations have been identified in <italic>APP</italic>, <italic>PSEN1</italic>, <italic>PSEN2</italic>, <italic>GRN</italic>, and <italic>MAPT </italic>according to the AD&amp;FTD mutation database.</s><s sid='112'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Con1' type='Con'></CoreSc1> In this study, we identified four pathogenic variants (p.M139T, p.L173F, and p.L392V in <italic>PSEN1 </italic>and g.10974_10975insCC in <italic>GRN</italic>), two of which were novel (p.L173F in <italic>PSEN1 </italic>and g.10974_10975insCC in <italic>GRN</italic>).</s><s sid='113'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Con1' type='Con'></CoreSc1> These four pathogenic variants explain 2.33% of our clinical AD cases.</s><s sid='114'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Met1' type='Met'></CoreSc1> However, the lack of additional familial cases prevents us from performing segregation analysis for other variants (<italic>MAPT </italic>p.V287I and p.A152T), and therefore their effect on risk for disease is unclear.</s><s sid='115'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Mot1' type='Mot'></CoreSc1> Additional genetic and functional analyses are required to confirm the effect of these variants on risk for AD.</s></p><p><s sid='116'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Res1' type='Res'></CoreSc1>On the other hand, for the <italic>GRN </italic>g.10974_10975insCC insertion, we confirmed that this novel mutation segregates with disease status.</s><s sid='117'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Obs1' type='Obs'></CoreSc1> This rare insertion mutation was not found in 459 older healthy Spanish controls.</s><s sid='118'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Res1' type='Res'></CoreSc1> In addition, our results from functional analyses were concordant with the known biological function of other known pathogenic <italic>GRN </italic>variants.</s><s sid='119'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Bac1' type='Bac'></CoreSc1> The <italic>GRN </italic>frameshift mutation creates a premature stop codon that results in nonsense-mediated decay leading to a decrease in <italic>GRN </italic>mRNA levels and protein levels in plasma and cerebrospinal fluid [<xref rid='B7' ref-type='bibr'>7</xref>,<xref rid='B29' ref-type='bibr'>29</xref>-<xref rid='B33' ref-type='bibr'>33</xref>].</s><s sid='120'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Res1' type='Res'></CoreSc1> We found that the <italic>GRN </italic>g.10974_10975insCC mutation carriers had extremely low plasma <italic>GRN </italic>levels, confirming the functional role of this novel mutation.</s></p><p><s sid='121'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Obs1' type='Obs'></CoreSc1>In <italic>MAPT</italic>, we found the p.A152T variant in exon 7 in two cases and no controls.</s><s sid='122'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Bac1' type='Bac'></CoreSc1> Recently, this variant was reported to be a risk factor for FTD and AD [<xref rid='B41' ref-type='bibr'>41</xref>].</s><s sid='123'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Bac1' type='Bac'></CoreSc1> The p.A152T variant was found in 0.69% of AD cases and 0.3% of controls (odds ratio = 2.3, <italic>P </italic>value = 0.004) [<xref rid='B41' ref-type='bibr'>41</xref>].</s><s sid='124'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Res1' type='Res'></CoreSc1> In our segregation analysis, p.A152T was absent in the healthy 69-year-old sibling of the proband, suggesting that p.A152T does segregate with disease in this family.</s><s sid='125'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Bac1' type='Bac'></CoreSc1> The p.V287I mutation was found in one chromosome out of 10,753 (corresponding to a frequency of 0.0186%) in the EVS database.</s><s sid='126'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Res1' type='Res'></CoreSc1> We found this variant in two cases (1.14%), which is a much higher frequency than that observed in the EVS database, suggesting that this variant could be associated with increased risk for disease.</s><s sid='127'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Bac1' type='Bac'></CoreSc1> So far, all of the <italic>MAPT </italic>variants in exon 4A were reported to be non-pathogenic (six out of six) in the AD&amp;FTD database [<xref rid='B44' ref-type='bibr'>44</xref>-<xref rid='B47' ref-type='bibr'>47</xref>].</s><s sid='128'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Bac1' type='Bac'></CoreSc1> In addition, previous studies have shown that the <italic>MAPT </italic>exon 4A is not expressed in the adult human cerebral cortex [<xref rid='B48' ref-type='bibr'>48</xref>,<xref rid='B49' ref-type='bibr'>49</xref>].</s><s sid='129'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Res1' type='Res'></CoreSc1> Although all six of the <italic>MAPT </italic>variants in exon 4A found in this study (including p.S318L, p.G213R, p.V224G, p.Q230R, and p.A297V) have higher frequencies in cases than in controls, these variants are more likely to be non-pathogenic according to previous findings and records.</s></p></sec><sec sec-type='conclusions'><title>Conclusions</title><p><s sid='130'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Con1' type='Con'></CoreSc1>In summary, we have identified two novel pathogenic variants: one in <italic>PSEN1 </italic>gene and the other in <italic>GRN</italic>.</s><s sid='131'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Met1' type='Met'></CoreSc1> We also conducted functional studies to validate the pathogenicity of the <italic>GRN </italic>variant.</s><s sid='132'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Con1' type='Con'></CoreSc1> Our findings are consistent with those that were previously reported by our group in a different population [<xref rid='B7' ref-type='bibr'>7</xref>] and that concluded the following: (a) there are likely more novel pathogenic variants causing an AD phenotype to be discovered in the AD (<italic>APP</italic>, <italic>PSEN1</italic>, and <italic>PSEN2</italic>) and FTD (<italic>MAPT </italic>and <italic>GRN</italic>) genes, (b) pathogenic variants located in such 'neurodegeneration' genes could be responsible for both EOAD and LOAD, and (c) mutations in <italic>GRN </italic>and <italic>MAPT</italic>, which have been considered traditionally 'FTD genes', can be present in individuals with a clinical presentation indistinguishable from that of typical AD.</s><s sid='133'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Con1' type='Con'></CoreSc1> Pathological information for the individual carriers for the novel <italic>GRN </italic>insertion and the novel <italic>MAPT </italic>variants was not available, so the AD diagnosis was based solely on clinical assessment.</s><s sid='134'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Bac1' type='Bac'></CoreSc1> Given other reports, it is more likely that these individuals are amnestic FTD cases but had a clinical presentation indistinguishable from that of AD [<xref rid='B7' ref-type='bibr'>7</xref>].</s><s sid='135'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Con1' type='Con'></CoreSc1> Identification of mutations in <italic>MAPT </italic>and <italic>GRN </italic>can help to make a more accurate diagnosis in these individuals.</s><s sid='136'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Con1' type='Con'></CoreSc1> These results highlight the necessity of screening both AD and FTD genes when autopsy confirmation of diagnosis is unavailable in demented individuals.</s></p></sec><sec><title>Abbreviations</title><p>AAO: age at onset; AD: Alzheimer's disease; AD&amp;FTD: Alzheimer Disease &amp; Frontotemporal Dementia; <italic>APP</italic>: amyloid-β precursor protein; bp: base pairs; ELISA: enzyme-linked immunosorbent assay; EOAD: early-onset Alzheimer's disease; EVS: Exome Variant Server; FTD: frontotemporal dementia; <italic>GRN</italic>: progranulin; LOAD: late-onset Alzheimer's disease; <italic>MAPT</italic>: microtubule-associated protein tau; NGS: next-generation sequencing; PCR: polymerase chain reaction; <italic>PSEN1</italic>: presenilin 1; <italic>PSEN2</italic>: presenilin 2; SPLINTER: short indel prediction by large deviation inference and nonlinear true frequency estimation by recursion.</p></sec><sec><title>Competing interests</title><p>The authors declare that they have no competing interests.</p></sec><sec><title>Authors' contributions</title><p>CC helped to conceive and design the experiments, to provide human samples and reagents, to analyze data, and to draft the manuscript. PP helped to conceive and design the experiments, to provide human samples and reagents, and to revise the manuscript. SCJ helped to conceive and design the experiments, to perform experiments, to acquire and analyze data, and to draft the manuscript. The Ibero-American Alzheimer Disease Genetics Group helped to provide human samples and reagents. SC helped to provide human samples and reagents, to perform experiments, and to acquire data. AG helped to provide human samples and reagents and to revise the manuscript. BC helped to perform experiments, to acquire data, and to draft the manuscript. BAB helped to analyze data and to revise the manuscript. All authors read and approved the final manuscript.</p></sec></body><back><sec><title>Acknowledgements</title><p>The Iberian Parkinson's Disease Genetics Study Group Researchers: Jordi Gascon, Jaume Campdelacreu, and Ramon Rene (Department of Neurology, Hospital Universitari de Bellvitge, Barcelona, Spain), Elena Alonso and Elena Lorenzo (Neurogenetics Laboratory, Division of Neurosciences, Center for Applied Medical Research University of Navarra School of Medicine), Jorge Lorenzo Otero and Eliana Pereyra (Department of Neuropsychology, Facultad de Medicina, Universidad de la República, Montevideo, Uruguay), Victor Raggio and Maria Mirta Rodríguez (Department of Genetics, Facultad de Medicina, Universidad de la Republica, Montevideo, Uruguay), Rodolfo Ferrando (Department of Nuclear Medicine, Facultad de Medicina, Universidad de la Republica, Montevideo, Uruguay), Pablo Martínez-Lage (Fundación CITA-Alzheimer, San Sebastian, Spain), and Manuel Seijo-Martínez (Department of Neurology, Hospital do Salnés, Pontevedra, Spain).</p><p>We gratefully thank Kevin Mayo for preparing the DNA samples and Gabe Haller and Francesco Vallania for help with sequencing data analysis. We acknowledge the expert technical assistance of the Genome Technology Access Center of Washington University in St. Louis. This work was supported by grants from the National Institutes of Health (P30-NS069329-01 and R01-AG035083). This study was supported by the FIMA project Center for Applied Medical Research (Centro de Investigación Medica Aplicada, CIMA) and a grant to PP from the Department of Health of the Government of Navarra (13085 and 3/2008).</p></sec><ref-list><ref id='B1'><mixed-citation publication-type='journal'><name><surname>Hebert</surname><given-names>LE</given-names></name><name><surname>Scherr</surname><given-names>PA</given-names></name><name><surname>Bienias</surname><given-names>JL</given-names></name><name><surname>Bennett</surname><given-names>DA</given-names></name><name><surname>Evans</surname><given-names>DA</given-names></name><article-title>Alzheimer disease in the US population: prevalence estimates using the 2000 census</article-title><source>Arch Neurol</source><year>2003</year><volume>60</volume><fpage>1119</fpage><lpage>1122</lpage><pub-id pub-id-type='doi'>10.1001/archneur.60.8.1119</pub-id><pub-id pub-id-type='pmid'>12925369</pub-id></mixed-citation></ref><ref id='B2'><mixed-citation publication-type='journal'><article-title>2009 Alzheimer's disease facts and figures</article-title><source>Alzheimers Dement</source><year>2009</year><volume>5</volume><fpage>234</fpage><lpage>270</lpage><pub-id pub-id-type='pmid'>19426951</pub-id></mixed-citation></ref><ref id='B3'><mixed-citation publication-type='journal'><name><surname>Goate</surname><given-names>A</given-names></name><name><surname>Chartier-Harlin</surname><given-names>M-C</given-names></name><name><surname>Mullan</surname><given-names>M</given-names></name><name><surname>Brown</surname><given-names>J</given-names></name><name><surname>Crawford</surname><given-names>F</given-names></name><name><surname>Fidani</surname><given-names>L</given-names></name><name><surname>Giuffra</surname><given-names>L</given-names></name><name><surname>Haynes</surname><given-names>A</given-names></name><name><surname>Irving</surname><given-names>N</given-names></name><name><surname>James</surname><given-names>L</given-names></name><name><surname>Mant</surname><given-names>R</given-names></name><name><surname>Newton</surname><given-names>P</given-names></name><name><surname>Rooke</surname><given-names>K</given-names></name><name><surname>Roques</surname><given-names>P</given-names></name><name><surname>Talbot</surname><given-names>C</given-names></name><name><surname>Pericak-Vance</surname><given-names>M</given-names></name><name><surname>Roses</surname><given-names>A</given-names></name><name><surname>Williamson</surname><given-names>R</given-names></name><name><surname>Rossor</surname><given-names>M</given-names></name><name><surname>Owen</surname><given-names>M</given-names></name><name><surname>Hardy</surname><given-names>J</given-names></name><article-title>Segregation of a missense mutation in the amyloid precursor protein gene with familial Alzheimer's disease</article-title><source>Nature</source><year>1991</year><volume>349</volume><fpage>704</fpage><lpage>706</lpage><pub-id pub-id-type='doi'>10.1038/349704a0</pub-id><pub-id pub-id-type='pmid'>1671712</pub-id></mixed-citation></ref><ref id='B4'><mixed-citation publication-type='journal'><name><surname>Sherrington</surname><given-names>R</given-names></name><name><surname>Rogaev</surname><given-names>EI</given-names></name><name><surname>Liang</surname><given-names>Y</given-names></name><name><surname>Rogaeva</surname><given-names>EA</given-names></name><name><surname>Levesque</surname><given-names>G</given-names></name><name><surname>Ikeda</surname><given-names>M</given-names></name><name><surname>Chi</surname><given-names>H</given-names></name><name><surname>Lin</surname><given-names>C</given-names></name><name><surname>Li</surname><given-names>G</given-names></name><name><surname>Holman</surname><given-names>K</given-names></name><name><surname>Tsuda</surname><given-names>T</given-names></name><name><surname>Mar</surname><given-names>L</given-names></name><name><surname>Foncin</surname><given-names>JF</given-names></name><name><surname>Bruni</surname><given-names>AC</given-names></name><name><surname>Montesi</surname><given-names>MP</given-names></name><name><surname>Sorbi</surname><given-names>S</given-names></name><name><surname>Rainero</surname><given-names>I</given-names></name><name><surname>Pinessi</surname><given-names>L</given-names></name><name><surname>Nee</surname><given-names>L</given-names></name><name><surname>Chumakov</surname><given-names>I</given-names></name><name><surname>Pollen</surname><given-names>D</given-names></name><name><surname>Brookes</surname><given-names>A</given-names></name><name><surname>Sanseau</surname><given-names>P</given-names></name><name><surname>Polinsky</surname><given-names>RJ</given-names></name><name><surname>Wasco</surname><given-names>W</given-names></name><name><surname>Da Silva</surname><given-names>HA</given-names></name><name><surname>Haines</surname><given-names>JL</given-names></name><name><surname>Perkicak-Vance</surname><given-names>MA</given-names></name><name><surname>Tanzi</surname><given-names>RE</given-names></name><name><surname>Roses</surname><given-names>AD</given-names></name><etal></etal><article-title>Cloning of a gene bearing missense mutations in early-onset familial Alzheimer's disease</article-title><source>Nature</source><year>1995</year><volume>375</volume><fpage>754</fpage><lpage>760</lpage><pub-id pub-id-type='doi'>10.1038/375754a0</pub-id><pub-id pub-id-type='pmid'>7596406</pub-id></mixed-citation></ref><ref id='B5'><mixed-citation publication-type='journal'><name><surname>Rogaev</surname><given-names>EI</given-names></name><name><surname>Sherrington</surname><given-names>R</given-names></name><name><surname>Rogaeva</surname><given-names>EA</given-names></name><name><surname>Levesque</surname><given-names>G</given-names></name><name><surname>Ikeda</surname><given-names>M</given-names></name><name><surname>Liang</surname><given-names>Y</given-names></name><name><surname>Chi</surname><given-names>H</given-names></name><name><surname>Lin</surname><given-names>C</given-names></name><name><surname>Holman</surname><given-names>K</given-names></name><name><surname>Tsuda</surname><given-names>T</given-names></name><name><surname>Mar</surname><given-names>L</given-names></name><name><surname>Sorbi</surname><given-names>S</given-names></name><name><surname>Nacmias</surname><given-names>B</given-names></name><name><surname>Piacentini</surname><given-names>S</given-names></name><name><surname>Amaducci</surname><given-names>L</given-names></name><name><surname>Chumakov</surname><given-names>I</given-names></name><name><surname>Cohen</surname><given-names>D</given-names></name><name><surname>Lannfelt</surname><given-names>L</given-names></name><name><surname>Fraser</surname><given-names>PE</given-names></name><name><surname>Rommens</surname><given-names>JM</given-names></name><name><surname>St George-Hyslop</surname><given-names>PH</given-names></name><article-title>Familial Alzheimer's disease in kindreds with missense mutations in a gene on chromosome 1 related to the Alzheimer's disease type 3 gene</article-title><source>Nature</source><year>1995</year><volume>376</volume><fpage>775</fpage><lpage>778</lpage><pub-id pub-id-type='doi'>10.1038/376775a0</pub-id><pub-id pub-id-type='pmid'>7651536</pub-id></mixed-citation></ref><ref id='B6'><mixed-citation publication-type='journal'><name><surname>Levy-Lahad</surname><given-names>E</given-names></name><name><surname>Wasco</surname><given-names>W</given-names></name><name><surname>Poorkaj</surname><given-names>P</given-names></name><name><surname>Romano</surname><given-names>DM</given-names></name><name><surname>Oshima</surname><given-names>J</given-names></name><name><surname>Pettingell</surname><given-names>WH</given-names></name><name><surname>Yu</surname><given-names>CE</given-names></name><name><surname>Jondro</surname><given-names>PD</given-names></name><name><surname>Schmidt</surname><given-names>SD</given-names></name><name><surname>Wang</surname><given-names>K</given-names></name><article-title>Candidate gene for the chromosome 1 familial Alzheimer's disease locus</article-title><source>Science</source><year>1995</year><volume>269</volume><fpage>973</fpage><lpage>977</lpage><pub-id pub-id-type='doi'>10.1126/science.7638622</pub-id><pub-id pub-id-type='pmid'>7638622</pub-id></mixed-citation></ref><ref id='B7'><mixed-citation publication-type='journal'><name><surname>Cruchaga</surname><given-names>C</given-names></name><name><surname>Chakraverty</surname><given-names>S</given-names></name><name><surname>Mayo</surname><given-names>K</given-names></name><name><surname>Vallania</surname><given-names>FL</given-names></name><name><surname>Mitra</surname><given-names>RD</given-names></name><name><surname>Faber</surname><given-names>K</given-names></name><name><surname>Williamson</surname><given-names>J</given-names></name><name><surname>Bird</surname><given-names>T</given-names></name><name><surname>Diaz-Arrastia</surname><given-names>R</given-names></name><name><surname>Foroud</surname><given-names>TM</given-names></name><name><surname>Boeve</surname><given-names>BF</given-names></name><name><surname>Graff-Radford</surname><given-names>NR</given-names></name><name><surname>St Jean</surname><given-names>P</given-names></name><name><surname>Lawson</surname><given-names>M</given-names></name><name><surname>Ehm</surname><given-names>MG</given-names></name><name><surname>Mayeux</surname><given-names>R</given-names></name><name><surname>Goate</surname><given-names>AM</given-names></name><article-title>Rare variants in APP, PSEN1 and PSEN2 increase risk for AD in late-onset Alzheimer's disease families</article-title><source>PLoS One</source><year>2012</year><volume>7</volume><fpage>e31039</fpage><pub-id pub-id-type='doi'>10.1371/journal.pone.0031039</pub-id><pub-id pub-id-type='pmid'>22312439</pub-id></mixed-citation></ref><ref id='B8'><mixed-citation publication-type='journal'><name><surname>Samaranch</surname><given-names>L</given-names></name><name><surname>Cervantes</surname><given-names>S</given-names></name><name><surname>Barabash</surname><given-names>A</given-names></name><name><surname>Alonso</surname><given-names>A</given-names></name><name><surname>Cabranes</surname><given-names>JA</given-names></name><name><surname>Lamet</surname><given-names>I</given-names></name><name><surname>Ancin</surname><given-names>I</given-names></name><name><surname>Lorenzo</surname><given-names>E</given-names></name><name><surname>Martinez-Lage</surname><given-names>P</given-names></name><name><surname>Marcos</surname><given-names>A</given-names></name><name><surname>Clarimon</surname><given-names>J</given-names></name><name><surname>Alcolea</surname><given-names>D</given-names></name><name><surname>Lleo</surname><given-names>A</given-names></name><name><surname>Blesa</surname><given-names>R</given-names></name><name><surname>Gomez-Isla</surname><given-names>T</given-names></name><name><surname>Pastor</surname><given-names>P</given-names></name><article-title>The effect of MAPT H1 and APOE epsilon4 on transition from mild cognitive impairment to dementia</article-title><source>J Alzheimers Dis</source><year>2010</year><volume>22</volume><fpage>1065</fpage><lpage>1071</lpage><pub-id pub-id-type='pmid'>20930301</pub-id></mixed-citation></ref><ref id='B9'><mixed-citation publication-type='journal'><name><surname>Cervantes</surname><given-names>S</given-names></name><name><surname>Samaranch</surname><given-names>L</given-names></name><name><surname>Vidal-Taboada</surname><given-names>JM</given-names></name><name><surname>Lamet</surname><given-names>I</given-names></name><name><surname>Bullido</surname><given-names>MJ</given-names></name><name><surname>Frank-Garcia</surname><given-names>A</given-names></name><name><surname>Coria</surname><given-names>F</given-names></name><name><surname>Lleo</surname><given-names>A</given-names></name><name><surname>Clarimon</surname><given-names>J</given-names></name><name><surname>Lorenzo</surname><given-names>E</given-names></name><name><surname>Alonso</surname><given-names>E</given-names></name><name><surname>Sanchez-Juan</surname><given-names>P</given-names></name><name><surname>Rodriguez-Rodriguez</surname><given-names>E</given-names></name><name><surname>Combarros</surname><given-names>O</given-names></name><name><surname>Rosich</surname><given-names>M</given-names></name><name><surname>Vilella</surname><given-names>E</given-names></name><name><surname>Pastor</surname><given-names>P</given-names></name><article-title>Genetic variation in APOE cluster region and Alzheimer's disease risk</article-title><source>Neurobiol Aging</source><year>2011</year><volume>32</volume><fpage>2107</fpage><lpage>e7 - 17</lpage><pub-id pub-id-type='pmid'>21752496</pub-id></mixed-citation></ref><ref id='B10'><mixed-citation publication-type='journal'><name><surname>Van Deerlin</surname><given-names>VM</given-names></name><name><surname>Wood</surname><given-names>EM</given-names></name><name><surname>Moore</surname><given-names>P</given-names></name><name><surname>Yuan</surname><given-names>W</given-names></name><name><surname>Forman</surname><given-names>MS</given-names></name><name><surname>Clark</surname><given-names>CM</given-names></name><name><surname>Neumann</surname><given-names>M</given-names></name><name><surname>Kwong</surname><given-names>LK</given-names></name><name><surname>Trojanowski</surname><given-names>JQ</given-names></name><name><surname>Lee</surname><given-names>VM</given-names></name><name><surname>Grossman</surname><given-names>M</given-names></name><article-title>Clinical, genetic, and pathologic characteristics of patients with frontotemporal dementia and progranulin mutations</article-title><source>Arch Neurol</source><year>2007</year><volume>64</volume><fpage>1148</fpage><lpage>1153</lpage><pub-id pub-id-type='doi'>10.1001/archneur.64.8.1148</pub-id><pub-id pub-id-type='pmid'>17698705</pub-id></mixed-citation></ref><ref id='B11'><mixed-citation publication-type='journal'><name><surname>Huey</surname><given-names>ED</given-names></name><name><surname>Grafman</surname><given-names>J</given-names></name><name><surname>Wassermann</surname><given-names>EM</given-names></name><name><surname>Pietrini</surname><given-names>P</given-names></name><name><surname>Tierney</surname><given-names>MC</given-names></name><name><surname>Ghetti</surname><given-names>B</given-names></name><name><surname>Spina</surname><given-names>S</given-names></name><name><surname>Baker</surname><given-names>M</given-names></name><name><surname>Hutton</surname><given-names>M</given-names></name><name><surname>Elder</surname><given-names>JW</given-names></name><name><surname>Berger</surname><given-names>SL</given-names></name><name><surname>Heflin</surname><given-names>KA</given-names></name><name><surname>Hardy</surname><given-names>J</given-names></name><name><surname>Momeni</surname><given-names>P</given-names></name><article-title>Characteristics of frontotemporal dementia patients with a Progranulin mutation</article-title><source>Ann Neurol</source><year>2006</year><volume>60</volume><fpage>374</fpage><lpage>380</lpage><pub-id pub-id-type='doi'>10.1002/ana.20969</pub-id><pub-id pub-id-type='pmid'>16983677</pub-id></mixed-citation></ref><ref id='B12'><mixed-citation publication-type='journal'><name><surname>McKhann</surname><given-names>G</given-names></name><name><surname>Drachman</surname><given-names>D</given-names></name><name><surname>Folstein</surname><given-names>M</given-names></name><name><surname>Katzman</surname><given-names>R</given-names></name><name><surname>Price</surname><given-names>D</given-names></name><name><surname>Stadlan</surname><given-names>EM</given-names></name><article-title>Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease</article-title><source>Neurology</source><year>1984</year><volume>34</volume><fpage>939</fpage><lpage>944</lpage><pub-id pub-id-type='doi'>10.1212/WNL.34.7.939</pub-id><pub-id pub-id-type='pmid'>6610841</pub-id></mixed-citation></ref><ref id='B13'><mixed-citation publication-type='journal'><name><surname>Haller</surname><given-names>G</given-names></name><name><surname>Druley</surname><given-names>T</given-names></name><name><surname>Vallania</surname><given-names>FL</given-names></name><name><surname>Mitra</surname><given-names>RD</given-names></name><name><surname>Li</surname><given-names>P</given-names></name><name><surname>Akk</surname><given-names>G</given-names></name><name><surname>Steinbach</surname><given-names>JH</given-names></name><name><surname>Breslau</surname><given-names>N</given-names></name><name><surname>Johnson</surname><given-names>E</given-names></name><name><surname>Hatsukami</surname><given-names>D</given-names></name><name><surname>Stitzel</surname><given-names>J</given-names></name><name><surname>Bierut</surname><given-names>LJ</given-names></name><name><surname>Goate</surname><given-names>AM</given-names></name><article-title>Rare missense variants in CHRNB4 are associated with reduced risk of nicotine dependence</article-title><source>Hum Mol Genet</source><year>2012</year><volume>21</volume><fpage>647</fpage><lpage>655</lpage><pub-id pub-id-type='doi'>10.1093/hmg/ddr498</pub-id><pub-id pub-id-type='pmid'>22042774</pub-id></mixed-citation></ref><ref id='B14'><mixed-citation publication-type='journal'><name><surname>Vallania</surname><given-names>FL</given-names></name><name><surname>Druley</surname><given-names>TE</given-names></name><name><surname>Ramos</surname><given-names>E</given-names></name><name><surname>Wang</surname><given-names>J</given-names></name><name><surname>Borecki</surname><given-names>I</given-names></name><name><surname>Province</surname><given-names>M</given-names></name><name><surname>Mitra</surname><given-names>RD</given-names></name><article-title>High-throughput discovery of rare insertions and deletions in large cohorts</article-title><source>Genome Res</source><year>2010</year><volume>20</volume><fpage>1711</fpage><lpage>1718</lpage><pub-id pub-id-type='doi'>10.1101/gr.109157.110</pub-id><pub-id pub-id-type='pmid'>21041413</pub-id></mixed-citation></ref><ref id='B15'><mixed-citation publication-type='other'><article-title>Alzheimer Disease &amp; Frontotemporal Dementia Mutation Database</article-title><ext-link ext-link-type='uri' xlink:href='http://www.molgen.ua.ac.be/Admutations'>http://www.molgen.ua.ac.be/Admutations</ext-link></mixed-citation></ref><ref id='B16'><mixed-citation publication-type='other'><article-title>Exome Variant Server</article-title><ext-link ext-link-type='uri' xlink:href='http://evs.gs.washington.edu/EVS'>http://evs.gs.washington.edu/EVS</ext-link></mixed-citation></ref><ref id='B17'><mixed-citation publication-type='other'><article-title>SeattleSeq Annotation</article-title><ext-link ext-link-type='uri' xlink:href='http://snp.gs.washington.edu/SeattleSeqAnnotation'>http://snp.gs.washington.edu/SeattleSeqAnnotation</ext-link></mixed-citation></ref><ref id='B18'><mixed-citation publication-type='journal'><name><surname>Campion</surname><given-names>D</given-names></name><name><surname>Flaman</surname><given-names>JM</given-names></name><name><surname>Brice</surname><given-names>A</given-names></name><name><surname>Hannequin</surname><given-names>D</given-names></name><name><surname>Dubois</surname><given-names>B</given-names></name><name><surname>Martin</surname><given-names>C</given-names></name><name><surname>Moreau</surname><given-names>V</given-names></name><name><surname>Charbonnier</surname><given-names>F</given-names></name><name><surname>Didierjean</surname><given-names>O</given-names></name><name><surname>Tardieu</surname><given-names>S</given-names></name><name><surname>Penet</surname><given-names>C</given-names></name><name><surname>Puel</surname><given-names>M</given-names></name><name><surname>Pasquier</surname><given-names>F</given-names></name><name><surname>Le Doze</surname><given-names>F</given-names></name><name><surname>Bellis</surname><given-names>G</given-names></name><name><surname>Calenda</surname><given-names>A</given-names></name><name><surname>Heilig</surname><given-names>R</given-names></name><name><surname>Martinez</surname><given-names>M</given-names></name><name><surname>Mallet</surname><given-names>J</given-names></name><name><surname>Bellis</surname><given-names>M</given-names></name><name><surname>Clerget-Darpoux</surname><given-names>F</given-names></name><name><surname>Agid</surname><given-names>Y</given-names></name><name><surname>Frebourg</surname><given-names>T</given-names></name><article-title>Mutations of the presenilin I gene in families with early-onset Alzheimer's disease</article-title><source>Hum Mol Genet</source><year>1995</year><volume>4</volume><fpage>2373</fpage><lpage>2377</lpage><pub-id pub-id-type='doi'>10.1093/hmg/4.12.2373</pub-id><pub-id pub-id-type='pmid'>8634712</pub-id></mixed-citation></ref><ref id='B19'><mixed-citation publication-type='journal'><name><surname>Campion</surname><given-names>D</given-names></name><name><surname>Dumanchin</surname><given-names>C</given-names></name><name><surname>Hannequin</surname><given-names>D</given-names></name><name><surname>Dubois</surname><given-names>B</given-names></name><name><surname>Belliard</surname><given-names>S</given-names></name><name><surname>Puel</surname><given-names>M</given-names></name><name><surname>Thomas-Anterion</surname><given-names>C</given-names></name><name><surname>Michon</surname><given-names>A</given-names></name><name><surname>Martin</surname><given-names>C</given-names></name><name><surname>Charbonnier</surname><given-names>F</given-names></name><name><surname>Raux</surname><given-names>G</given-names></name><name><surname>Camuzat</surname><given-names>A</given-names></name><name><surname>Penet</surname><given-names>C</given-names></name><name><surname>Mesnage</surname><given-names>V</given-names></name><name><surname>Martinez</surname><given-names>M</given-names></name><name><surname>Clerget-Darpoux</surname><given-names>F</given-names></name><name><surname>Brice</surname><given-names>A</given-names></name><name><surname>Frebourg</surname><given-names>T</given-names></name><article-title>Early-onset autosomal dominant Alzheimer disease: prevalence, genetic heterogeneity, and mutation spectrum</article-title><source>Am J Hum Genet</source><year>1999</year><volume>65</volume><fpage>664</fpage><lpage>670</lpage><pub-id pub-id-type='doi'>10.1086/302553</pub-id><pub-id pub-id-type='pmid'>10441572</pub-id></mixed-citation></ref><ref id='B20'><mixed-citation publication-type='journal'><name><surname>Queralt</surname><given-names>R</given-names></name><name><surname>Ezquerra</surname><given-names>M</given-names></name><name><surname>Castellvi</surname><given-names>M</given-names></name><name><surname>Lleo</surname><given-names>A</given-names></name><name><surname>Blesa</surname><given-names>R</given-names></name><name><surname>Oliva</surname><given-names>R</given-names></name><article-title>Detection of the presenilin 1 gene mutation (M139T) in early-onset familial Alzheimer disease in Spain</article-title><source>Neurosci Lett</source><year>2001</year><volume>299</volume><fpage>239</fpage><lpage>241</lpage><pub-id pub-id-type='doi'>10.1016/S0304-3940(01)01498-7</pub-id><pub-id pub-id-type='pmid'>11165779</pub-id></mixed-citation></ref><ref id='B21'><mixed-citation publication-type='journal'><name><surname>Lleo</surname><given-names>A</given-names></name><name><surname>Blesa</surname><given-names>R</given-names></name><name><surname>Queralt</surname><given-names>R</given-names></name><name><surname>Ezquerra</surname><given-names>M</given-names></name><name><surname>Molinuevo</surname><given-names>JL</given-names></name><name><surname>Pena-Casanova</surname><given-names>J</given-names></name><name><surname>Rojo</surname><given-names>A</given-names></name><name><surname>Oliva</surname><given-names>R</given-names></name><article-title>Frequency of mutations in the presenilin and amyloid precursor protein genes in early-onset Alzheimer disease in Spain</article-title><source>Arch Neurol</source><year>2002</year><volume>59</volume><fpage>1759</fpage><lpage>1763</lpage><pub-id pub-id-type='doi'>10.1001/archneur.59.11.1759</pub-id><pub-id pub-id-type='pmid'>12433263</pub-id></mixed-citation></ref><ref id='B22'><mixed-citation publication-type='journal'><name><surname>Campion</surname><given-names>D</given-names></name><name><surname>Brice</surname><given-names>A</given-names></name><name><surname>Hannequin</surname><given-names>D</given-names></name><name><surname>Tardieu</surname><given-names>S</given-names></name><name><surname>Dubois</surname><given-names>B</given-names></name><name><surname>Calenda</surname><given-names>A</given-names></name><name><surname>Brun</surname><given-names>E</given-names></name><name><surname>Penet</surname><given-names>C</given-names></name><name><surname>Tayot</surname><given-names>J</given-names></name><name><surname>Martinez</surname><given-names>M</given-names></name><name><surname>Bellis</surname><given-names>M</given-names></name><name><surname>Mallet</surname><given-names>J</given-names></name><name><surname>Agid</surname><given-names>Y</given-names></name><name><surname>Clerget-Darpoux</surname><given-names>F</given-names></name><article-title>A large pedigree with early-onset Alzheimer's disease: clinical, neuropathologic, and genetic characterization</article-title><source>Neurology</source><year>1995</year><volume>45</volume><fpage>80</fpage><lpage>85</lpage><pub-id pub-id-type='doi'>10.1212/WNL.45.1.80</pub-id><pub-id pub-id-type='pmid'>7824141</pub-id></mixed-citation></ref><ref id='B23'><mixed-citation publication-type='journal'><name><surname>Raux</surname><given-names>G</given-names></name><name><surname>Guyant-Marechal</surname><given-names>L</given-names></name><name><surname>Martin</surname><given-names>C</given-names></name><name><surname>Bou</surname><given-names>J</given-names></name><name><surname>Penet</surname><given-names>C</given-names></name><name><surname>Brice</surname><given-names>A</given-names></name><name><surname>Hannequin</surname><given-names>D</given-names></name><name><surname>Frebourg</surname><given-names>T</given-names></name><name><surname>Campion</surname><given-names>D</given-names></name><article-title>Molecular diagnosis of autosomal dominant early onset Alzheimer's disease: an update</article-title><source>J Med Genet</source><year>2005</year><volume>42</volume><fpage>793</fpage><lpage>795</lpage><pub-id pub-id-type='doi'>10.1136/jmg.2005.033456</pub-id><pub-id pub-id-type='pmid'>16033913</pub-id></mixed-citation></ref><ref id='B24'><mixed-citation publication-type='journal'><name><surname>Ikeuchi</surname><given-names>T</given-names></name><name><surname>Kaneko</surname><given-names>H</given-names></name><name><surname>Miyashita</surname><given-names>A</given-names></name><name><surname>Nozaki</surname><given-names>H</given-names></name><name><surname>Kasuga</surname><given-names>K</given-names></name><name><surname>Tsukie</surname><given-names>T</given-names></name><name><surname>Tsuchiya</surname><given-names>M</given-names></name><name><surname>Imamura</surname><given-names>T</given-names></name><name><surname>Ishizu</surname><given-names>H</given-names></name><name><surname>Aoki</surname><given-names>K</given-names></name><name><surname>Ishikawa</surname><given-names>A</given-names></name><name><surname>Onodera</surname><given-names>O</given-names></name><name><surname>Kuwano</surname><given-names>R</given-names></name><name><surname>Nishizawa</surname><given-names>M</given-names></name><article-title>Mutational analysis in early-onset familial dementia in the Japanese population. The role of PSEN1 and MAPT R406W mutations</article-title><source>Dement Geriatr Cogn Disord</source><year>2008</year><volume>26</volume><fpage>43</fpage><lpage>49</lpage><pub-id pub-id-type='doi'>10.1159/000141483</pub-id><pub-id pub-id-type='pmid'>18587238</pub-id></mixed-citation></ref><ref id='B25'><mixed-citation publication-type='journal'><name><surname>Kasuga</surname><given-names>K</given-names></name><name><surname>Ohno</surname><given-names>T</given-names></name><name><surname>Ishihara</surname><given-names>T</given-names></name><name><surname>Miyashita</surname><given-names>A</given-names></name><name><surname>Kuwano</surname><given-names>R</given-names></name><name><surname>Onodera</surname><given-names>O</given-names></name><name><surname>Nishizawa</surname><given-names>M</given-names></name><name><surname>Ikeuchi</surname><given-names>T</given-names></name><article-title>Depression and psychiatric symptoms preceding onset of dementia in a family with early-onset Alzheimer disease with a novel PSEN1 mutation</article-title><source>J Neurol</source><year>2009</year><volume>256</volume><fpage>1351</fpage><lpage>1353</lpage><pub-id pub-id-type='doi'>10.1007/s00415-009-5096-4</pub-id><pub-id pub-id-type='pmid'>19280102</pub-id></mixed-citation></ref><ref id='B26'><mixed-citation publication-type='journal'><name><surname>Aldudo</surname><given-names>J</given-names></name><name><surname>Bullido</surname><given-names>MJ</given-names></name><name><surname>Frank</surname><given-names>A</given-names></name><name><surname>Valdivieso</surname><given-names>F</given-names></name><article-title>Missense mutation E318G of the presenilin-1 gene appears to be a nonpathogenic polymorphism</article-title><source>Ann Neurol</source><year>1998</year><volume>44</volume><fpage>985</fpage><lpage>986</lpage><pub-id pub-id-type='doi'>10.1002/ana.410440624</pub-id><pub-id pub-id-type='pmid'>9851450</pub-id></mixed-citation></ref><ref id='B27'><mixed-citation publication-type='journal'><name><surname>Dermaut</surname><given-names>B</given-names></name><name><surname>Cruts</surname><given-names>M</given-names></name><name><surname>Slooter</surname><given-names>AJ</given-names></name><name><surname>Van Gestel</surname><given-names>S</given-names></name><name><surname>De Jonghe</surname><given-names>C</given-names></name><name><surname>Vanderstichele</surname><given-names>H</given-names></name><name><surname>Vanmechelen</surname><given-names>E</given-names></name><name><surname>Breteler</surname><given-names>MM</given-names></name><name><surname>Hofman</surname><given-names>A</given-names></name><name><surname>van Duijn</surname><given-names>CM</given-names></name><name><surname>Van Broeckhoven</surname><given-names>C</given-names></name><article-title>The Glu318Gly substitution in presenilin 1 is not causally related to Alzheimer disease</article-title><source>Am J Hum Genet</source><year>1999</year><volume>64</volume><fpage>290</fpage><lpage>292</lpage><pub-id pub-id-type='doi'>10.1086/302200</pub-id><pub-id pub-id-type='pmid'>9915968</pub-id></mixed-citation></ref><ref id='B28'><mixed-citation publication-type='journal'><name><surname>Helisalmi</surname><given-names>S</given-names></name><name><surname>Hiltunen</surname><given-names>M</given-names></name><name><surname>Mannermaa</surname><given-names>A</given-names></name><name><surname>Koivisto</surname><given-names>AM</given-names></name><name><surname>Lehtovirta</surname><given-names>M</given-names></name><name><surname>Alafuzoff</surname><given-names>I</given-names></name><name><surname>Ryynanen</surname><given-names>M</given-names></name><name><surname>Soininen</surname><given-names>H</given-names></name><article-title>Is the presenilin-1 E318G missense mutation a risk factor for Alzheimer's disease?</article-title><source>Neurosci Lett</source><year>2000</year><volume>278</volume><fpage>65</fpage><lpage>68</lpage><pub-id pub-id-type='doi'>10.1016/S0304-3940(99)00891-5</pub-id><pub-id pub-id-type='pmid'>10643802</pub-id></mixed-citation></ref><ref id='B29'><mixed-citation publication-type='journal'><name><surname>Yu</surname><given-names>CE</given-names></name><name><surname>Bird</surname><given-names>TD</given-names></name><name><surname>Bekris</surname><given-names>LM</given-names></name><name><surname>Montine</surname><given-names>TJ</given-names></name><name><surname>Leverenz</surname><given-names>JB</given-names></name><name><surname>Steinbart</surname><given-names>E</given-names></name><name><surname>Galloway</surname><given-names>NM</given-names></name><name><surname>Feldman</surname><given-names>H</given-names></name><name><surname>Woltjer</surname><given-names>R</given-names></name><name><surname>Miller</surname><given-names>CA</given-names></name><name><surname>Wood</surname><given-names>EM</given-names></name><name><surname>Grossman</surname><given-names>M</given-names></name><name><surname>McCluskey</surname><given-names>L</given-names></name><name><surname>Clark</surname><given-names>CM</given-names></name><name><surname>Neumann</surname><given-names>M</given-names></name><name><surname>Danek</surname><given-names>A</given-names></name><name><surname>Galasko</surname><given-names>DR</given-names></name><name><surname>Arnold</surname><given-names>SE</given-names></name><name><surname>Chen-Plotkin</surname><given-names>A</given-names></name><name><surname>Karydas</surname><given-names>A</given-names></name><name><surname>Miller</surname><given-names>BL</given-names></name><name><surname>Trojanowski</surname><given-names>JQ</given-names></name><name><surname>Lee</surname><given-names>VM</given-names></name><name><surname>Schellenberg</surname><given-names>GD</given-names></name><name><surname>Van Deerlin</surname><given-names>VM</given-names></name><article-title>The spectrum of mutations in progranulin: a collaborative study screening 545 cases of neurodegeneration</article-title><source>Arch Neurol</source><year>2010</year><volume>67</volume><fpage>161</fpage><lpage>170</lpage><pub-id pub-id-type='doi'>10.1001/archneurol.2009.328</pub-id><pub-id pub-id-type='pmid'>20142524</pub-id></mixed-citation></ref><ref id='B30'><mixed-citation publication-type='journal'><name><surname>Gass</surname><given-names>J</given-names></name><name><surname>Cannon</surname><given-names>A</given-names></name><name><surname>Mackenzie</surname><given-names>IR</given-names></name><name><surname>Boeve</surname><given-names>B</given-names></name><name><surname>Baker</surname><given-names>M</given-names></name><name><surname>Adamson</surname><given-names>J</given-names></name><name><surname>Crook</surname><given-names>R</given-names></name><name><surname>Melquist</surname><given-names>S</given-names></name><name><surname>Kuntz</surname><given-names>K</given-names></name><name><surname>Petersen</surname><given-names>R</given-names></name><name><surname>Josephs</surname><given-names>K</given-names></name><name><surname>Pickering-Brown</surname><given-names>SM</given-names></name><name><surname>Graff-Radford</surname><given-names>N</given-names></name><name><surname>Uitti</surname><given-names>R</given-names></name><name><surname>Dickson</surname><given-names>D</given-names></name><name><surname>Wszolek</surname><given-names>Z</given-names></name><name><surname>Gonzalez</surname><given-names>J</given-names></name><name><surname>Beach</surname><given-names>TG</given-names></name><name><surname>Bigio</surname><given-names>E</given-names></name><name><surname>Johnson</surname><given-names>N</given-names></name><name><surname>Weintraub</surname><given-names>S</given-names></name><name><surname>Mesulam</surname><given-names>M</given-names></name><name><surname>White</surname><given-names>CL</given-names></name><name><surname>Woodruff</surname><given-names>B</given-names></name><name><surname>Caselli</surname><given-names>R</given-names></name><name><surname>Hsiung</surname><given-names>GY</given-names></name><name><surname>Feldman</surname><given-names>H</given-names></name><name><surname>Knopman</surname><given-names>D</given-names></name><name><surname>Hutton</surname><given-names>M</given-names></name><name><surname>Rademakers</surname><given-names>R</given-names></name><article-title>Mutations in progranulin are a major cause of ubiquitin-positive frontotemporal lobar degeneration</article-title><source>Hum Mol Genet</source><year>2006</year><volume>15</volume><fpage>2988</fpage><lpage>3001</lpage><pub-id pub-id-type='doi'>10.1093/hmg/ddl241</pub-id><pub-id pub-id-type='pmid'>16950801</pub-id></mixed-citation></ref><ref id='B31'><mixed-citation publication-type='journal'><name><surname>Carecchio</surname><given-names>M</given-names></name><name><surname>Fenoglio</surname><given-names>C</given-names></name><name><surname>De Riz</surname><given-names>M</given-names></name><name><surname>Guidi</surname><given-names>I</given-names></name><name><surname>Comi</surname><given-names>C</given-names></name><name><surname>Cortini</surname><given-names>F</given-names></name><name><surname>Venturelli</surname><given-names>E</given-names></name><name><surname>Restelli</surname><given-names>I</given-names></name><name><surname>Cantoni</surname><given-names>C</given-names></name><name><surname>Bresolin</surname><given-names>N</given-names></name><name><surname>Monaco</surname><given-names>F</given-names></name><name><surname>Scarpini</surname><given-names>E</given-names></name><name><surname>Galimberti</surname><given-names>D</given-names></name><article-title>Progranulin plasma levels as potential biomarker for the identification of GRN deletion carriers. A case with atypical onset as clinical amnestic Mild Cognitive Impairment converted to Alzheimer's disease</article-title><source>J Neurol Sci</source><year>2009</year><volume>287</volume><fpage>291</fpage><lpage>293</lpage><pub-id pub-id-type='doi'>10.1016/j.jns.2009.07.011</pub-id><pub-id pub-id-type='pmid'>19683260</pub-id></mixed-citation></ref><ref id='B32'><mixed-citation publication-type='journal'><name><surname>Benussi</surname><given-names>L</given-names></name><name><surname>Binetti</surname><given-names>G</given-names></name><name><surname>Sina</surname><given-names>E</given-names></name><name><surname>Gigola</surname><given-names>L</given-names></name><name><surname>Bettecken</surname><given-names>T</given-names></name><name><surname>Meitinger</surname><given-names>T</given-names></name><name><surname>Ghidoni</surname><given-names>R</given-names></name><article-title>A novel deletion in progranulin gene is associated with FTDP-17 and CBS</article-title><source>Neurobiol Aging</source><year>2008</year><volume>29</volume><fpage>427</fpage><lpage>435</lpage><pub-id pub-id-type='doi'>10.1016/j.neurobiolaging.2006.10.028</pub-id><pub-id pub-id-type='pmid'>17157414</pub-id></mixed-citation></ref><ref id='B33'><mixed-citation publication-type='journal'><name><surname>Le Ber</surname><given-names>I</given-names></name><name><surname>Camuzat</surname><given-names>A</given-names></name><name><surname>Hannequin</surname><given-names>D</given-names></name><name><surname>Pasquier</surname><given-names>F</given-names></name><name><surname>Guedj</surname><given-names>E</given-names></name><name><surname>Rovelet-Lecrux</surname><given-names>A</given-names></name><name><surname>Hahn-Barma</surname><given-names>V</given-names></name><name><surname>van der Zee</surname><given-names>J</given-names></name><name><surname>Clot</surname><given-names>F</given-names></name><name><surname>Bakchine</surname><given-names>S</given-names></name><name><surname>Puel</surname><given-names>M</given-names></name><name><surname>Ghanim</surname><given-names>M</given-names></name><name><surname>Lacomblez</surname><given-names>L</given-names></name><name><surname>Mikol</surname><given-names>J</given-names></name><name><surname>Deramecourt</surname><given-names>V</given-names></name><name><surname>Lejeune</surname><given-names>P</given-names></name><name><surname>de la Sayette</surname><given-names>V</given-names></name><name><surname>Belliard</surname><given-names>S</given-names></name><name><surname>Vercelletto</surname><given-names>M</given-names></name><name><surname>Meyrignac</surname><given-names>C</given-names></name><name><surname>Van Broeckhoven</surname><given-names>C</given-names></name><name><surname>Lambert</surname><given-names>JC</given-names></name><name><surname>Verpillat</surname><given-names>P</given-names></name><name><surname>Campion</surname><given-names>D</given-names></name><name><surname>Habert</surname><given-names>MO</given-names></name><name><surname>Dubois</surname><given-names>B</given-names></name><name><surname>Brice</surname><given-names>A</given-names></name><article-title>Phenotype variability in progranulin mutation carriers: a clinical, neuropsychological, imaging and genetic study</article-title><source>Brain</source><year>2008</year><volume>131</volume><fpage>732</fpage><lpage>746</lpage><pub-id pub-id-type='doi'>10.1093/brain/awn012</pub-id><pub-id pub-id-type='pmid'>18245784</pub-id></mixed-citation></ref><ref id='B34'><mixed-citation publication-type='journal'><name><surname>Behrens</surname><given-names>MI</given-names></name><name><surname>Mukherjee</surname><given-names>O</given-names></name><name><surname>Tu</surname><given-names>PH</given-names></name><name><surname>Liscic</surname><given-names>RM</given-names></name><name><surname>Grinberg</surname><given-names>LT</given-names></name><name><surname>Carter</surname><given-names>D</given-names></name><name><surname>Paulsmeyer</surname><given-names>K</given-names></name><name><surname>Taylor-Reinwald</surname><given-names>L</given-names></name><name><surname>Gitcho</surname><given-names>M</given-names></name><name><surname>Norton</surname><given-names>JB</given-names></name><name><surname>Chakraverty</surname><given-names>S</given-names></name><name><surname>Goate</surname><given-names>AM</given-names></name><name><surname>Morris</surname><given-names>JC</given-names></name><name><surname>Cairns</surname><given-names>NJ</given-names></name><article-title>Neuropathologic heterogeneity in HDDD1: a familial frontotemporal lobar degeneration with ubiquitin-positive inclusions and progranulin mutation</article-title><source>Alzheimer Dis Assoc Disord</source><year>2007</year><volume>21</volume><fpage>1</fpage><lpage>7</lpage><pub-id pub-id-type='doi'>10.1097/WAD.0b013e31803083f2</pub-id><pub-id pub-id-type='pmid'>17334266</pub-id></mixed-citation></ref><ref id='B35'><mixed-citation publication-type='journal'><name><surname>Mukherjee</surname><given-names>O</given-names></name><name><surname>Pastor</surname><given-names>P</given-names></name><name><surname>Cairns</surname><given-names>NJ</given-names></name><name><surname>Chakraverty</surname><given-names>S</given-names></name><name><surname>Kauwe</surname><given-names>JS</given-names></name><name><surname>Shears</surname><given-names>S</given-names></name><name><surname>Behrens</surname><given-names>MI</given-names></name><name><surname>Budde</surname><given-names>J</given-names></name><name><surname>Hinrichs</surname><given-names>AL</given-names></name><name><surname>Norton</surname><given-names>J</given-names></name><name><surname>Levitch</surname><given-names>D</given-names></name><name><surname>Taylor-Reinwald</surname><given-names>L</given-names></name><name><surname>Gitcho</surname><given-names>M</given-names></name><name><surname>Tu</surname><given-names>PH</given-names></name><name><surname>Tenenholz Grinberg</surname><given-names>L</given-names></name><name><surname>Liscic</surname><given-names>RM</given-names></name><name><surname>Armendariz</surname><given-names>J</given-names></name><name><surname>Morris</surname><given-names>JC</given-names></name><name><surname>Goate</surname><given-names>AM</given-names></name><article-title>HDDD2 is a familial frontotemporal lobar degeneration with ubiquitin-positive, tau-negative inclusions caused by a missense mutation in the signal peptide of progranulin</article-title><source>Ann Neurol</source><year>2006</year><volume>60</volume><fpage>314</fpage><lpage>322</lpage><pub-id pub-id-type='doi'>10.1002/ana.20963</pub-id><pub-id pub-id-type='pmid'>16983685</pub-id></mixed-citation></ref><ref id='B36'><mixed-citation publication-type='journal'><name><surname>Chiang</surname><given-names>HH</given-names></name><name><surname>Rosvall</surname><given-names>L</given-names></name><name><surname>Brohede</surname><given-names>J</given-names></name><name><surname>Axelman</surname><given-names>K</given-names></name><name><surname>Bjork</surname><given-names>BF</given-names></name><name><surname>Nennesmo</surname><given-names>I</given-names></name><name><surname>Robins</surname><given-names>T</given-names></name><name><surname>Graff</surname><given-names>C</given-names></name><article-title>Progranulin mutation causes frontotemporal dementia in the Swedish Karolinska family</article-title><source>Alzheimers Dement</source><year>2008</year><volume>4</volume><fpage>414</fpage><lpage>420</lpage><pub-id pub-id-type='doi'>10.1016/j.jalz.2008.09.001</pub-id><pub-id pub-id-type='pmid'>19012866</pub-id></mixed-citation></ref><ref id='B37'><mixed-citation publication-type='journal'><name><surname>Bird</surname><given-names>TD</given-names></name><article-title>Progranulin plasma levels in the diagnosis of frontotemporal dementia</article-title><source>Brain</source><year>2009</year><volume>132</volume><fpage>568</fpage><lpage>569</lpage><pub-id pub-id-type='doi'>10.1093/brain/awp009</pub-id><pub-id pub-id-type='pmid'>19224898</pub-id></mixed-citation></ref><ref id='B38'><mixed-citation publication-type='journal'><name><surname>Finch</surname><given-names>N</given-names></name><name><surname>Baker</surname><given-names>M</given-names></name><name><surname>Crook</surname><given-names>R</given-names></name><name><surname>Swanson</surname><given-names>K</given-names></name><name><surname>Kuntz</surname><given-names>K</given-names></name><name><surname>Surtees</surname><given-names>R</given-names></name><name><surname>Bisceglio</surname><given-names>G</given-names></name><name><surname>Rovelet-Lecrux</surname><given-names>A</given-names></name><name><surname>Boeve</surname><given-names>B</given-names></name><name><surname>Petersen</surname><given-names>RC</given-names></name><name><surname>Dickson</surname><given-names>DW</given-names></name><name><surname>Younkin</surname><given-names>SG</given-names></name><name><surname>Deramecourt</surname><given-names>V</given-names></name><name><surname>Crook</surname><given-names>J</given-names></name><name><surname>Graff-Radford</surname><given-names>NR</given-names></name><name><surname>Rademakers</surname><given-names>R</given-names></name><article-title>Plasma progranulin levels predict progranulin mutation status in frontotemporal dementia patients and asymptomatic family members</article-title><source>Brain</source><year>2009</year><volume>132</volume><fpage>583</fpage><lpage>591</lpage><pub-id pub-id-type='doi'>10.1093/brain/awn352</pub-id><pub-id pub-id-type='pmid'>19158106</pub-id></mixed-citation></ref><ref id='B39'><mixed-citation publication-type='journal'><name><surname>Cruchaga</surname><given-names>C</given-names></name><name><surname>Graff</surname><given-names>C</given-names></name><name><surname>Chiang</surname><given-names>HH</given-names></name><name><surname>Wang</surname><given-names>J</given-names></name><name><surname>Hinrichs</surname><given-names>AL</given-names></name><name><surname>Spiegel</surname><given-names>N</given-names></name><name><surname>Bertelsen</surname><given-names>S</given-names></name><name><surname>Mayo</surname><given-names>K</given-names></name><name><surname>Norton</surname><given-names>JB</given-names></name><name><surname>Morris</surname><given-names>JC</given-names></name><name><surname>Goate</surname><given-names>A</given-names></name><article-title>Association of TMEM106B gene polymorphism with age at onset in granulin mutation carriers and plasma granulin protein levels</article-title><source>Arch Neurol</source><year>2011</year><volume>68</volume><fpage>581</fpage><lpage>586</lpage><pub-id pub-id-type='doi'>10.1001/archneurol.2010.350</pub-id><pub-id pub-id-type='pmid'>21220649</pub-id></mixed-citation></ref><ref id='B40'><mixed-citation publication-type='journal'><name><surname>Mukherjee</surname><given-names>O</given-names></name><name><surname>Wang</surname><given-names>J</given-names></name><name><surname>Gitcho</surname><given-names>M</given-names></name><name><surname>Chakraverty</surname><given-names>S</given-names></name><name><surname>Taylor-Reinwald</surname><given-names>L</given-names></name><name><surname>Shears</surname><given-names>S</given-names></name><name><surname>Kauwe</surname><given-names>JS</given-names></name><name><surname>Norton</surname><given-names>J</given-names></name><name><surname>Levitch</surname><given-names>D</given-names></name><name><surname>Bigio</surname><given-names>EH</given-names></name><name><surname>Hatanpaa</surname><given-names>KJ</given-names></name><name><surname>White</surname><given-names>CL</given-names></name><name><surname>Morris</surname><given-names>JC</given-names></name><name><surname>Cairns</surname><given-names>NJ</given-names></name><name><surname>Goate</surname><given-names>A</given-names></name><article-title>Molecular characterization of novel progranulin (GRN) mutations in frontotemporal dementia</article-title><source>Hum Mutat</source><year>2008</year><volume>29</volume><fpage>512</fpage><lpage>521</lpage><pub-id pub-id-type='doi'>10.1002/humu.20681</pub-id><pub-id pub-id-type='pmid'>18183624</pub-id></mixed-citation></ref><ref id='B41'><mixed-citation publication-type='journal'><name><surname>Coppola</surname><given-names>G</given-names></name><name><surname>Chinnathambi</surname><given-names>S</given-names></name><name><surname>Jiyong Lee</surname><given-names>J</given-names></name><name><surname>Dombroski</surname><given-names>BA</given-names></name><name><surname>Baker</surname><given-names>MC</given-names></name><name><surname>Soto-Ortolaza</surname><given-names>AI</given-names></name><name><surname>Lee</surname><given-names>SE</given-names></name><name><surname>Klein</surname><given-names>E</given-names></name><name><surname>Huang</surname><given-names>AY</given-names></name><name><surname>Sears</surname><given-names>R</given-names></name><name><surname>Lane</surname><given-names>JR</given-names></name><name><surname>Karydas</surname><given-names>AM</given-names></name><name><surname>Kenet</surname><given-names>RO</given-names></name><name><surname>Biernat</surname><given-names>J</given-names></name><name><surname>Wang</surname><given-names>LS</given-names></name><name><surname>Cotman</surname><given-names>CW</given-names></name><name><surname>Decarli</surname><given-names>CS</given-names></name><name><surname>Levey</surname><given-names>AI</given-names></name><name><surname>Ringman</surname><given-names>JM</given-names></name><name><surname>Mendez</surname><given-names>MF</given-names></name><name><surname>Chui</surname><given-names>HC</given-names></name><name><surname>Le Ber</surname><given-names>I</given-names></name><name><surname>Brice</surname><given-names>A</given-names></name><name><surname>Lupton</surname><given-names>MK</given-names></name><name><surname>Preza</surname><given-names>E</given-names></name><name><surname>Lovestone</surname><given-names>S</given-names></name><name><surname>Powell</surname><given-names>J</given-names></name><name><surname>Graff-Radford</surname><given-names>N</given-names></name><name><surname>Petersen</surname><given-names>RC</given-names></name><name><surname>Boeve</surname><given-names>BF</given-names></name><etal></etal><article-title>Evidence for a role of the rare p.A152T variant in MAPT in increasing the risk for FTD-spectrum and Alzheimer's diseases</article-title><source>Hum Mol Genet</source><year>2012</year><volume>21</volume><fpage>3500</fpage><lpage>3512</lpage><pub-id pub-id-type='doi'>10.1093/hmg/dds161</pub-id><pub-id pub-id-type='pmid'>22556362</pub-id></mixed-citation></ref><ref id='B42'><mixed-citation publication-type='journal'><name><surname>Kara</surname><given-names>E</given-names></name><name><surname>Ling</surname><given-names>H</given-names></name><name><surname>Pittman</surname><given-names>AM</given-names></name><name><surname>Shaw</surname><given-names>K</given-names></name><name><surname>de Silva</surname><given-names>R</given-names></name><name><surname>Simone</surname><given-names>R</given-names></name><name><surname>Holton</surname><given-names>JL</given-names></name><name><surname>Warren</surname><given-names>JD</given-names></name><name><surname>Rohrer</surname><given-names>JD</given-names></name><name><surname>Xiromerisiou</surname><given-names>G</given-names></name><name><surname>Lees</surname><given-names>A</given-names></name><name><surname>Hardy</surname><given-names>J</given-names></name><name><surname>Houlden</surname><given-names>H</given-names></name><name><surname>Revesz</surname><given-names>T</given-names></name><article-title>The MAPT p.A152T variant is a risk factor associated with tauopathies with atypical clinical and neuropathological features</article-title><source>Neurobiol Aging</source><year>2012</year><volume>33</volume><fpage>2231.e7</fpage><lpage>2231.e14</lpage><pub-id pub-id-type='doi'>10.1016/j.neurobiolaging.2012.04.006</pub-id><pub-id pub-id-type='pmid'>22595371</pub-id></mixed-citation></ref><ref id='B43'><mixed-citation publication-type='journal'><name><surname>Hyman</surname><given-names>BT</given-names></name><name><surname>Phelps</surname><given-names>CH</given-names></name><name><surname>Beach</surname><given-names>TG</given-names></name><name><surname>Bigio</surname><given-names>EH</given-names></name><name><surname>Cairns</surname><given-names>NJ</given-names></name><name><surname>Carrillo</surname><given-names>MC</given-names></name><name><surname>Dickson</surname><given-names>DW</given-names></name><name><surname>Duyckaerts</surname><given-names>C</given-names></name><name><surname>Frosch</surname><given-names>MP</given-names></name><name><surname>Masliah</surname><given-names>E</given-names></name><name><surname>Mirra</surname><given-names>SS</given-names></name><name><surname>Nelson</surname><given-names>PT</given-names></name><name><surname>Schneider</surname><given-names>JA</given-names></name><name><surname>Thal</surname><given-names>DR</given-names></name><name><surname>Thies</surname><given-names>B</given-names></name><name><surname>Trojanowski</surname><given-names>JQ</given-names></name><name><surname>Vinters</surname><given-names>HV</given-names></name><name><surname>Montine</surname><given-names>TJ</given-names></name><article-title>National Institute on Aging-Alzheimer's Association guidelines for the neuropathologic assessment of Alzheimer's disease</article-title><source>Alzheimers Dement</source><year>2012</year><volume>8</volume><fpage>1</fpage><lpage>13</lpage><pub-id pub-id-type='doi'>10.1016/j.jalz.2011.10.007</pub-id><pub-id pub-id-type='pmid'>22265587</pub-id></mixed-citation></ref><ref id='B44'><mixed-citation publication-type='journal'><name><surname>Poorkaj</surname><given-names>P</given-names></name><name><surname>Bird</surname><given-names>TD</given-names></name><name><surname>Wijsman</surname><given-names>E</given-names></name><name><surname>Nemens</surname><given-names>E</given-names></name><name><surname>Garruto</surname><given-names>RM</given-names></name><name><surname>Anderson</surname><given-names>L</given-names></name><name><surname>Andreadis</surname><given-names>A</given-names></name><name><surname>Wiederholt</surname><given-names>WC</given-names></name><name><surname>Raskind</surname><given-names>M</given-names></name><name><surname>Schellenberg</surname><given-names>GD</given-names></name><article-title>Tau is a candidate gene for chromosome 17 frontotemporal dementia</article-title><source>Ann Neurol</source><year>1998</year><volume>43</volume><fpage>815</fpage><lpage>825</lpage><pub-id pub-id-type='doi'>10.1002/ana.410430617</pub-id><pub-id pub-id-type='pmid'>9629852</pub-id></mixed-citation></ref><ref id='B45'><mixed-citation publication-type='journal'><name><surname>Stanford</surname><given-names>PM</given-names></name><name><surname>Brooks</surname><given-names>WS</given-names></name><name><surname>Teber</surname><given-names>ET</given-names></name><name><surname>Hallupp</surname><given-names>M</given-names></name><name><surname>McLean</surname><given-names>C</given-names></name><name><surname>Halliday</surname><given-names>GM</given-names></name><name><surname>Martins</surname><given-names>RN</given-names></name><name><surname>Kwok</surname><given-names>JB</given-names></name><name><surname>Schofield</surname><given-names>PR</given-names></name><article-title>Frequency of tau mutations in familial and sporadic frontotemporal dementia and other tauopathies</article-title><source>J Neurol</source><year>2004</year><volume>251</volume><fpage>1098</fpage><lpage>1104</lpage><pub-id pub-id-type='pmid'>15372253</pub-id></mixed-citation></ref><ref id='B46'><mixed-citation publication-type='journal'><name><surname>Rademakers</surname><given-names>R</given-names></name><name><surname>Cruts</surname><given-names>M</given-names></name><name><surname>van Broeckhoven</surname><given-names>C</given-names></name><article-title>The role of tau (MAPT) in frontotemporal dementia and related tauopathies</article-title><source>Hum Mutat</source><year>2004</year><volume>24</volume><fpage>277</fpage><lpage>295</lpage><pub-id pub-id-type='doi'>10.1002/humu.20086</pub-id><pub-id pub-id-type='pmid'>15365985</pub-id></mixed-citation></ref><ref id='B47'><mixed-citation publication-type='journal'><name><surname>Ingelson</surname><given-names>M</given-names></name><name><surname>Fabre</surname><given-names>SF</given-names></name><name><surname>Lilius</surname><given-names>L</given-names></name><name><surname>Andersen</surname><given-names>C</given-names></name><name><surname>Viitanen</surname><given-names>M</given-names></name><name><surname>Almkvist</surname><given-names>O</given-names></name><name><surname>Wahlund</surname><given-names>LO</given-names></name><name><surname>Lannfelt</surname><given-names>L</given-names></name><article-title>Increased risk for frontotemporal dementia through interaction between tau polymorphisms and apolipoprotein E epsilon4</article-title><source>Neuroreport</source><year>2001</year><volume>12</volume><fpage>905</fpage><lpage>909</lpage><pub-id pub-id-type='doi'>10.1097/00001756-200104170-00008</pub-id><pub-id pub-id-type='pmid'>11303757</pub-id></mixed-citation></ref><ref id='B48'><mixed-citation publication-type='journal'><name><surname>Himmler</surname><given-names>A</given-names></name><article-title>Structure of the bovine tau gene: alternatively spliced transcripts generate a protein family</article-title><source>Mol Cell Biol</source><year>1989</year><volume>9</volume><fpage>1389</fpage><lpage>1396</lpage><pub-id pub-id-type='pmid'>2498650</pub-id></mixed-citation></ref><ref id='B49'><mixed-citation publication-type='journal'><name><surname>Andreadis</surname><given-names>A</given-names></name><name><surname>Brown</surname><given-names>WM</given-names></name><name><surname>Kosik</surname><given-names>KS</given-names></name><article-title>Structure and novel exons of the human tau gene</article-title><source>Biochemistry</source><year>1992</year><volume>31</volume><fpage>10626</fpage><lpage>10633</lpage><pub-id pub-id-type='doi'>10.1021/bi00158a027</pub-id><pub-id pub-id-type='pmid'>1420178</pub-id></mixed-citation></ref></ref-list></back></article></PAPER>